WO2007094548A2 - Berberrubine derivatives having antifungal activities - Google Patents
Berberrubine derivatives having antifungal activities Download PDFInfo
- Publication number
- WO2007094548A2 WO2007094548A2 PCT/KR2006/004607 KR2006004607W WO2007094548A2 WO 2007094548 A2 WO2007094548 A2 WO 2007094548A2 KR 2006004607 W KR2006004607 W KR 2006004607W WO 2007094548 A2 WO2007094548 A2 WO 2007094548A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- butylbenzyl
- chloride
- tert
- berberrubine
- Prior art date
Links
- 150000003831 berberrubine derivatives Chemical class 0.000 title claims abstract description 22
- 230000000843 anti-fungal effect Effects 0.000 title abstract description 33
- 150000001875 compounds Chemical class 0.000 claims description 267
- GYFSYEVKFOOLFZ-UHFFFAOYSA-N Berberrubine Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GYFSYEVKFOOLFZ-UHFFFAOYSA-N 0.000 claims description 127
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 122
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 88
- GLYPKDKODVRYGP-UHFFFAOYSA-O berberrubine Natural products C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GLYPKDKODVRYGP-UHFFFAOYSA-O 0.000 claims description 85
- GLYPKDKODVRYGP-UHFFFAOYSA-N burberrubine Natural products C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(=O)C1=C2 GLYPKDKODVRYGP-UHFFFAOYSA-N 0.000 claims description 85
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 41
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- RMXQKRNQRBAYEZ-UHFFFAOYSA-N 13-(4-isopropylbenzyl)berberrubine Chemical compound C=12C3=CC=4OCOC=4C=C3CCN2C=C2C(=O)C(OC)=CC=C2C=1CC1=CC=C(C(C)C)C=C1 RMXQKRNQRBAYEZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 150000004820 halides Chemical group 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 102000005469 Chitin Synthase Human genes 0.000 abstract description 34
- 230000002401 inhibitory effect Effects 0.000 abstract description 25
- 108700040089 Chitin synthases Proteins 0.000 abstract description 21
- 241000233866 Fungi Species 0.000 abstract description 15
- 244000000008 fungal human pathogen Species 0.000 abstract description 10
- 229920002101 Chitin Polymers 0.000 abstract description 9
- 230000003389 potentiating effect Effects 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 219
- 238000005160 1H NMR spectroscopy Methods 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 53
- 239000000243 solution Substances 0.000 description 48
- 238000003756 stirring Methods 0.000 description 34
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 208000031888 Mycoses Diseases 0.000 description 14
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 229940121375 antifungal agent Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000222122 Candida albicans Species 0.000 description 11
- 239000003429 antifungal agent Substances 0.000 description 11
- 229940095731 candida albicans Drugs 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- 125000006488 t-butyl benzyl group Chemical group 0.000 description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 101710164537 Chitin synthase 1 Proteins 0.000 description 7
- -1 corn sweetener Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 6
- MPEKZIYOLQCWLL-UHFFFAOYSA-N 5-(bromomethyl)-1,2,3-trifluorobenzene Chemical compound FC1=CC(CBr)=CC(F)=C1F MPEKZIYOLQCWLL-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- JPFWJDMDPLEUBD-UHFFFAOYSA-N Polyoxin D Natural products OC1C(O)C(C(NC(=O)C(C(O)C(O)COC(N)=O)N)C(O)=O)OC1N1C(=O)NC(=O)C(C(O)=O)=C1 JPFWJDMDPLEUBD-UHFFFAOYSA-N 0.000 description 6
- 150000003832 berberine derivatives Chemical class 0.000 description 6
- 108700006921 chitin synthase 2 Proteins 0.000 description 6
- JPFWJDMDPLEUBD-ITJAGOAWSA-N polyoxorim Polymers O[C@@H]1[C@H](O)[C@@H]([C@H](NC(=O)[C@H]([C@H](O)[C@@H](O)COC(N)=O)N)C(O)=O)O[C@H]1N1C(=O)NC(=O)C(C(O)=O)=C1 JPFWJDMDPLEUBD-ITJAGOAWSA-N 0.000 description 6
- 229940081969 saccharomyces cerevisiae Drugs 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 5
- 229960003942 amphotericin b Drugs 0.000 description 5
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 5
- 229940093265 berberine Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 201000007336 Cryptococcosis Diseases 0.000 description 4
- 241000221204 Cryptococcus neoformans Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 101100113485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-3 gene Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000222126 [Candida] glabrata Species 0.000 description 4
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 4
- 230000008436 biogenesis Effects 0.000 description 4
- 208000032343 candida glabrata infection Diseases 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000002576 ketones Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YXTHBZLABLYGEE-UHFFFAOYSA-N 1-(bromomethyl)-4-propan-2-ylbenzene Chemical compound CC(C)C1=CC=C(CBr)C=C1 YXTHBZLABLYGEE-UHFFFAOYSA-N 0.000 description 3
- QZNQSIHCDAGZIA-UHFFFAOYSA-N 1-(bromomethyl)-4-tert-butylbenzene Chemical compound CC(C)(C)C1=CC=C(CBr)C=C1 QZNQSIHCDAGZIA-UHFFFAOYSA-N 0.000 description 3
- 101100465387 Caenorhabditis elegans pas-6 gene Proteins 0.000 description 3
- 241000222173 Candida parapsilosis Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000235645 Pichia kudriavzevii Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000003836 berberines Chemical group 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940055022 candida parapsilosis Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 244000053095 fungal pathogen Species 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 101150032598 hisG gene Proteins 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- AVMHMVJVHYGDOO-NSCUHMNNSA-N (e)-1-bromobut-2-ene Chemical compound C\C=C\CBr AVMHMVJVHYGDOO-NSCUHMNNSA-N 0.000 description 2
- UWLHSHAHTBJTBA-UHFFFAOYSA-N 1-iodooctane Chemical compound CCCCCCCCI UWLHSHAHTBJTBA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 2
- 241001465318 Aspergillus terreus Species 0.000 description 2
- 101150085479 CHS2 gene Proteins 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241000950447 Clavispora lusitaniae ATCC 42720 Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101100167214 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) chsA gene Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000293032 Mucor ramosissimus Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 2
- HFEHLDPGIKPNKL-UHFFFAOYSA-N allyl iodide Chemical compound ICC=C HFEHLDPGIKPNKL-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012449 sabouraud dextrose agar Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- JDNPUJCKXLOHOW-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CBr)C=C1 JDNPUJCKXLOHOW-UHFFFAOYSA-N 0.000 description 1
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QEGDRYOJTONTLO-UHFFFAOYSA-N 5-(bromomethyl)-1,2,3-trimethoxybenzene Chemical compound COC1=CC(CBr)=CC(OC)=C1OC QEGDRYOJTONTLO-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 101100167204 Candida albicans CHS2 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101710164541 Chitin synthase 3 Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 150000007980 azole derivatives Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940011182 cobalt acetate Drugs 0.000 description 1
- QAHREYKOYSIQPH-UHFFFAOYSA-L cobalt(II) acetate Chemical compound [Co+2].CC([O-])=O.CC([O-])=O QAHREYKOYSIQPH-UHFFFAOYSA-L 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000008686 ergosterol biosynthesis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000009085 invasive aspergillosis Diseases 0.000 description 1
- 208000036732 invasive candidiasis Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K31/00—Actuating devices; Operating means; Releasing devices
- F16K31/02—Actuating devices; Operating means; Releasing devices electric; magnetic
- F16K31/06—Actuating devices; Operating means; Releasing devices electric; magnetic using a magnet, e.g. diaphragm valves, cutting off by means of a liquid
- F16K31/10—Actuating devices; Operating means; Releasing devices electric; magnetic using a magnet, e.g. diaphragm valves, cutting off by means of a liquid with additional mechanism between armature and closure member
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K27/00—Construction of housing; Use of materials therefor
- F16K27/02—Construction of housing; Use of materials therefor of lift valves
- F16K27/0236—Diaphragm cut-off apparatus
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K27/00—Construction of housing; Use of materials therefor
- F16K27/02—Construction of housing; Use of materials therefor of lift valves
- F16K27/029—Electromagnetically actuated valves
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16K—VALVES; TAPS; COCKS; ACTUATING-FLOATS; DEVICES FOR VENTING OR AERATING
- F16K31/00—Actuating devices; Operating means; Releasing devices
- F16K31/02—Actuating devices; Operating means; Releasing devices electric; magnetic
- F16K31/06—Actuating devices; Operating means; Releasing devices electric; magnetic using a magnet, e.g. diaphragm valves, cutting off by means of a liquid
- F16K31/0603—Multiple-way valves
- F16K31/0641—Multiple-way valves the valve member being a diaphragm
Definitions
- the present invention relates to a berberrubine derivative having superior antifungal activity, more particularly to a berberrubine derivative having inhibitory activity against chitin synthase, which participates in the synthesis of chitin and is essential in the growth of fungi, and having potent antifungal activity against human pathogenic fungi, which is represented by the following formula (1):
- amphotericin B which was developed in the 1960s, is still being used in clinical treatment of systemic mycoses in spite of its high toxicity (Georgopadakou, N. H. et al., Science, 264, 371-373, 1994).
- the occurrence of fungal strains resistant to existing antifungal agents is on the increase (Rex, J. H. et al., Antimicrob. Agents Chemother., 39, 1-8, 1995).
- the antifungal agents used for clinical purposes are mostly polyenes, azole derivatives, allylamines and thiocarbamates. They either interact with ergosterol, the cell membrane component of fungi, or inhibit the synthesis of ergosterol.
- ergosterol the cell membrane component of fungi
- thiocarbamates the antifungal agents used for clinical purposes.
- amphotericin B is still widely used because of the lack of superior medicines.
- fungi Since fungi have cell walls that are different from those of mammals, the cell wall of fungi has long been seen as a good target.
- the cell wall of fungi maintains the cell structure, prevents the cell from being destroyed by osmosis while participating in the transfer of macromolecules.
- the cell wall of fungi is made up of chitin, ⁇ -glucan, ⁇ - glucan, mannan, etc. Of these, chitin, or ⁇ -l,3-glucan, has been the main target for the development of antifungal agents.
- Chitin is a homopolymer constructed from units of N-acetyl-d-glucosamine linked with ⁇ -1,4 glycoside bond.
- Chitin is synthesized by chitin synthases 1, 2 and 3.
- Candida albicans harbours three chitin synthases 1, 2 and 3, which are analogous in terms of structure and function to those of Saccharomyces cerevisiae chitin synthases 2, 1 and 3, respectively.
- Chitin synthase 1 from Candida albicans participates in septum formation during cell division, while chitin synthase 3 participates in chitin ring formation during the formation of daughter cells from mother cells and the cell wall biogenesis.
- chitin synthase 2 recovers severely damaged cell wall during cell division (Mio T. et al., J. Bacteriol, 178, 2416-2419, 1996).
- chitin synthases 1 and 3 are the main targets for the development of new cell wall biogenesis inhibitors, as they are known as essential enzymes.
- Berberine the main component of Coptis chinensis Fr., which has been known as
- berberrubine The compound obtained by pyrolyzing berberine at high temperature to replace the methoxy group at the C-9 position with a hydroxyl group is called berberrubine.
- the hydroxyl group at the C-9 position of berberrubine is present in the form of either a ketone group or a hydroxyl group and is reversibly transformed, as shown in the following formula:
- Korean Patent No. 258,849 discloses that berberine derivatives in which various benzyl groups are introduced at the C- 13 position or at the same time alkoxy groups are introduced at the C-9 and C-IO positions instead of two methoxy groups.
- berberine derivatives represented by the following formula, wherein R 1 and R 2 are -O-CH -O- or OCH , R 3 is H, R 4 is OCH and R 5 is benzyl or substituted
- the berberrubine derivatives of the present invention in which methoxy is present at the C- 10 position and a variety of C -C alkoxy are substituted at the C-9 position, showed more potent antifungal activities than those of the substituted berberine derivatives of Korean Patent No. 258,849, in which identical substituents (methoxy) are substituted at the C-9 and C-IO positions (see Table 3 and Table 4 below).
- berberrubine derivatives introduced alkoxy groups at the C-9 position only, berberrubine used as a intermediate was synthesized by pyrolysis.
- the present inventors worked to synthesize new berberrubine derivatives that can solve the problems of the existing antifungal agents, have selective inhibitory effect against chitin synthase, that are absent in mammals, and have superior antifungal activity.
- novel compounds of the present invention effectively inhibit chitin synthases, and thus have very potent antifungal activity against human pathogenic fungi such as Candida albicans ATCC 10231, Candida lusitaniae ATCC 42720, Candida krusei ATCC 6258, Candida tropicalis ATCC 13803, Candida glabrata ATCC 48435, Candida parapsilosis ATCC 34136, Cryptococcus neoformans ATCC 36556, Aspergillus fumigatus ATCC 16424, Aspergillus flavus ATCC 64025, Aspergillus terreus ATCC 46941, Mucor ramosissimus ATCC 90286, Candida albicans A207(clinical isolate), Trichophyton mentagrophytes ATCC 9533, etc.
- human pathogenic fungi such as Candida albicans ATCC 10231, Candida lusitaniae ATCC 42720, Candida krusei ATCC 6258, Candida tropicalis ATCC 13803, Candida
- the present invention is characterized by a berberrubine derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof:
- the present invention is also characterized by an antifungal agent which comprises the berberrubine derivative represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound of the present invention which is represented by the aforementioned formula (1) can be used in the form of a pharmaceutically acceptable salt, which may be a halide or an acid adduct. More specifically, the pharmaceutically acceptable salt of the compound represented by the aforementioned formula (1) may be selected from fluoride, chloride, bromide, iodide, hydroxide, nitrate, sulfate, acetate, phosphate, tartarate, succinate, lactate, citrate, fumarate, maleate, glycolate, formate, malate, benzoate, methanesulfonate, benzenesulfonate, asparaginate, salicylate, glycerate and ascorbinate.
- a pharmaceutically acceptable salt which may be a halide or an acid adduct. More specifically, the pharmaceutically acceptable salt of the compound represented by the aforementioned formula (1) may be selected from fluoride, chloride, bromide, iodide, hydroxide, nitrate,
- the compound of the present invention which is represented by the aforementioned formula (1) may be in the form of solvate (e.g., hydrate).
- R is benzyl or substituted benzyl having 1 to 4 substituents selected from halogen, C -C alkyl, C -C haloalkyl, C -C alkoxy and C -C haloalkoxy and R is
- the novel compound in accordance with the present invention has superior inhibitory activity against chitin synthase (chitin synthase 1), which participates in chitin biogenesis, and potent antifungal activity against human pathogenic fungi.
- the present invention also provides a pharmaceutical composition comprising the compound represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the pharmaceutical composition of the present invention comprises the compound represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable excipient.
- the pharmaceutical composition of the present invention may be prepared into: oral administration form including tablet, capsule and syrup; injection form; suppository form; external application form including ointment, cream, lotion and liquid; etc.
- the present invention also provides a method for the prevention and the treatment of systemic infection by fungi in mammals by administering an effective dosage of the compound, represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof.
- the compound of the present invention can be orally administered in the form of a tablet, a capsule (sustained release or controlled release), a pill, powder, a granule, an elixir, a tincture, a suspension, a syrup or an emulsion. Also, it can be administered by the method well known by those skilled in the art, e.g., intravenously, intraperitoneally, locally (e.g., eye drops), subcutaneously, intramuscularly, transdermally (e.g., patches), etc.
- the dosage of the compound of the present invention is determined by considering age, weight, sex, physical conditions, etc. of a patient, seriousness of the conditions to be treated, administration route, liver or lung function of the patient, the particular compound or the salt to be used, etc. An average doctor, veterinarian or clinician may easily determine the pharmaceutically effective dosage required for the prevention or inhibition of the development of the condition.
- the oral dosage for attaining the purpose of the present invention is about 0.01-100 mg/kg/day, preferably about 0.01-10 mg/kg/day, and more preferably about 0.1-5.0 mg/kg/day.
- the composition is provided in the form of tablet comprising the active ingredient in 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 mg in order to find the adequate dosage for the particular patient.
- a drug comprises the active ingredient in the range from about 0.01 mg to about 500 mg, preferably from about 1 mg to about 100 mg.
- the most preferred dosage is 0.1-10 mg/kg/min.
- the compound of the present invention may be administered once, twice, three times or four times daily. Also, preferably, the compound of the present invention may be administered either intranasally using an adequate intranasal carrier or transdermally using a commonly used transdermal patch. It is obvious that the transdermal administration ensures a continuous administration.
- the compound of the present invention may be mixed with a pharmaceutically acceptable diluent or excipient (collectively, the 'excipient'), which is selected considering the type of administration.
- a pharmaceutically acceptable diluent or excipient collectively, the 'excipient'
- the active ingredient in case of oral administration using tablet or capsule, may be mixed with non-toxic, pharmaceutically acceptable excipient, such as lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, calcium phosphate dibasic, calcium sulfate, mannitol, sorbitol, etc.
- non-toxic, pharmaceutically acceptable excipient such as lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, calcium phosphate dibasic, calcium sulfate, mannitol, sorbitol, etc.
- non-toxic, pharmaceutically acceptable excipient such as ethanol, glycerol, water, etc.
- an adequate binder, lubricant, dispersant or colorant may be added to the mixture solution.
- the binder may be natural sugars such as starch, gelatin, glucose and ⁇ -lactose, natural or synthetic rubbers such as corn sweetener, acacia and sodium alginate, carboxymethyl- cellulose, polyethylene glycol, wax, etc.
- the lubricant may be sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc.
- the dispersant may be starch, methylcellulose, agar, bentonite, xanthan rubber, etc.
- an electrophilic alkyl substituent (R-X, where X is halogen atom) is reacted with the compound represented by the formula (Ia) or (Ib) to attain the novel compound represented by the aforementioned formula (Ic), wherein both C-9 and C- 13 positions are substituted by the functional groups.
- 8-acetonyldihydroberberine represented by the aforementioned formula (3) and the introduction of the functional group R at the C-9 position of the berberrubine derivative represented by the aforementioned formula (Ia) are carried out, respectively, using an adequate electrophilic alkyl substituent.
- a suitable organic solvent and a commonly used organic or inorganic base may be added, if necessary.
- a commonly used organic solvent selected from methylene chloride, chloroform, acetonitrile, dimethyl- formamide, tetrahydrofuran, etc.
- organic bases such as amine or inorganic bases such as alkali metal hydride, hydroxide, carbonate, etc.
- the base may be selected from ammonia, triethylamine, sodium hydride, potassium hydride, lithium hydride, potassium carbonate, or sodium carbonate, etc.
- reaction intermediate or the target compound represented by the aforementioned formula (1) obtained by the preparation process may be separated and purified by the commonly utilized method, such as chromatography and recrys- tallization.
- reaction solution was concentrated under reduced pressure and then washed with ethyl ether.
- 1.1 g of 13-(3,4,5-trifluoro)berberine was obtained from silica gel column chromatography. During the chromatography, a 1:20 organic solvent mixture of methanol and chloroform was used as an eluent.
- Example 5 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.25 mL of propyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.32 g of 13-(4-tert-butylbenzyl)-9-0- propylber- berrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl 3 ).
- Example 12 13-(4-i'e/t-Butylbenzyl)-9-0-(6-chlorohexyl)berberrubine iodide
- Example 16 13-(4-l'e/t-Butylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine bromide (Compound No. 16) [ 185] 0.34 g of 13-(4-terf-butylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 7, except that
- Example 17 13 -(4-Isopropylbenzyl)-9-0-propylberberrubine iodide
- Example 6 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.25 mL of propyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.33 g of 13-(4-isopropylbenzyl)-9-O- propylber- berrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl 3 ).
- Example 18 13 -(4-Isopropylbenzyl)-9-0-butylberberrubine iodide
- Example 20 13 -(4-Isopropylbenzyl)-9-0-octylberberrubine iodide (Compound No. 20)
- Example 21 13-(4-Isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide (Compound No. 21) [205] 0.25 g of 13-(4-isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that l-iodo-3-propanol was used instead of propyl iodide. [206] ⁇ H-NMR (DMSO-J 300 MHz) ⁇ 10.26 (s, IH), 7.65 (m, 2H), 7.37 (d, 2H), 7.03
- Example 22 13-(4-Isopropylbenzyl)-9-0-(6-chlorohexyl)berberrubine iodide
- Example 23 13 -(4-Isopropylbenzyl)-9-0-allylberberrubine iodide
- Example 1 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(3,4,5-trifluorobenzyl)-9-O-butylberberrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl ).
- Example 30 13-(3,4,5-trimethoxybenzyl)-9-0-butylberberrubine iodide
- Example 2 was dissolved in 50 mL of acetonitrile (CH CN). After completely the mixture dissolving by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(3,4,5-trimethoxybenzyl)-9-O-butylberberrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl ).
- Example 3 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(4-trifluoromethoxybenzyl)-9-0- butylber- berrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl 3 ).
- Example 35 13-(4-Trifluoromethoxybenzyl)-9-0-(4-te/t - butylbenzyl)berberrubine bromide (Compound No. 35)
- Example 36 13-(4-Trifluoromethylbenzyl)-9-0-butylberberrubine iodide
- Example 4 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(4-trifluoromethylbenzyl)-9-O-butylberbe ⁇ ubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl ).
- Example 48 13-(4-l'e/t-Butylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine chloride (Compound No. 48)
- Example 50 13-(4-Isopropylbenzyl)-9-0-butylberberrubine chloride
- Example 54 13-(4-Isopropylbenzyl)-9-0-(6-chlorohexyl)berberrubine chloride (Compound No. 54)
- Example 57 13-(4-Isopropylbenzyl)-9-0-(4-te/t-butylbenzyl)berberrubine chloride (Compound No. 57)
- Example 58 13-(4-Isopropylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine chloride (Compound No. 58)
- Example 61 13-(3,4,5-Trifluorobenzyl)-9-0-(4-l'e/t-butylbenzyl)berberrubine chloride (Compound No. 61)
- Example 64 13-(3,4,5-Trimethoxybenzyl)-9-0-(4-te/t- butylbenzyl)berberrubine chloride (Compound No. 64)
- Example 65 13-(4-Trifluoromethoxybenzyl)-9-0-butylberberrubine chloride
- Example 70 13-(4-Trifluoromethylbenzyl)-9-0-(4-te/*-butylbenzy l)berberrubine chloride (Compound No. 70)
- novel compound of the present invention represented by the formula (1) can be prepared into various preparation forms depending on the purposes specified. Some non-restrictive preparation examples of the compound of the present invention represented by the aforementioned formula (1) are given below.
- An injection form was prepared by mixing 100 mg of the active ingredient, 180 mg of mannitol, 26 mg of Na HPO • 12H O and 2974 mg of distilled water.
- Test Example 1 Preparation of chitin synthase 1 crude enzyme of Candida albicans
- the cells were collected and suspended in a 50 mM Tris-HCl (pH 7.5) buffer solution containing 5 mM magnesium acetate. After centrifugation at 8,000 x g for 10 minutes, the pellets were suspended in the same Tris-HCl buffer solution. The suspension was divided into aliquots in 50 mL conical test tubes. After adding glass beads, the cells were disrupted by vigorously vortexing with an interval of 30 seconds. The cell residues were removed by centrifuging at 3,000 x g for 5 minutes. The supernatant was ultra- centrifuged at 130,000 x g for 1 hour.
- the resultant pellets were collected and suspended in 50 mM Tris-HCl (pH 7.5) containing 33 % glycerol, to a final volume of 1.6 mg/g (wet weight) of yeast used. The suspension was divided into aliquots and kept at -70 °C until it is used.
- Test Example 2 Preparation of chitin synthase 2 crude enzyme of Sac- charomyces cerevisiae
- ECY38-38A(pAS6) (MATa chsl-23 chs2::LEU2 cal llcsdl ura 3-52 trp 1-1 leu 2-2 pAS6) strain, which can produce the chitin synthase 2 only.
- the strain was inoculated with the YPG culture medium (1 % yeast extract, 2 % peptone, 2 % galactose) and cultured at 30 °C overnight. Then, it was inoculated with a fresh YPG culture medium and cultured for 15-17 hours until the Absorbance at 550nm reaches 1.0.
- the cells were collected and suspended in 50 mM Tris-HCl (pH 7.5) buffer containing 5 mM magnesium acetate.
- the pellets were suspended in the same Tris-HCl buffer solution.
- the suspension was divided into aliquots in 50 mL conical test tubes. After adding the glass beads, the cells were disrupted by vigorously vortexing with an interval of 30 seconds. The cell residues were removed by centrifuging at 3,000xg for 5 minutes. The supernatant was ultra- centrifuged at 130,000xg for 1 hour. The resultant pellets were collected and suspended in 50 mM Tris-HCl (pH 7.5) containing 33 % glycerol, to a final volume of 1.6 mg/g (wet weight) of yeast used. The suspension was divided into aliquots and kept at -70 °C until it is used.
- Test Example 3 In vitro enzyme assays for chitin synthase 1 of Candida albicans and chitin synthase 2 of Saccharomyces cerevisiae
- control group was not added with a test sample in the reaction mixture and that of the untreated group contained neither the test sample nor the crude enzyme .
- Test Example 4 Antifungal activity against human pathogenic fungi
- MIC In vitro antifungal activity against human pathogenic fungi was examined for the compounds that showed potent inhibitory activities against the chitin synthases and amphotericin B, a control compound. The result is given in Table 4 below.
- test sample solution was diluted two-fold and inoculated with a fungal suspension to reach a final inoculum size of 5 x 10 to 2.5 xlO cell/mL .
- the Cryptococcus neoformans strain was cultured in the RPMI 1640 medium for 72 hours. Other strains were cultured for 48 hours. MIC was determined as the lowest concentration of the compound that completely inhibited the growth of the fungi by comparing with a control not containing the compound.
- novel compounds in accordance with the present invention were confirmed to have superior antifungal activity.
- the compounds of the present invention in which a methoxy group is introduced at the C-10 position and a relatively long C -C alkoxy chain is introduced at the C-9 position showed 10-fold or more of antifungal activities against most of the 12 human pathogenic fungi. In some strains, the antifungal activity was 32 to 64-fold more potent.
- Test Example 5 Acute oral toxicity
- Each compound was suspended in 1 % car- boxymethylcellulose (CMC), and orally and abdominally administered to 6-week-old male ICR mice. General symptoms, weight change and deaths were observed for a week under normal breeding condition. Then, an autopsy was performed on the mice. The results are given in Table 5 below. Table 5
- the iodides compound Nos. 7, 8, 17 and 18 and the chlorides compound Nos. 39, 40, 49 and 50 showed superior inhibitory activities against the chitin synthases, which are essential in the growth of fungi.
- fungi are eukaryotic organisms, most of conventional antifungal agents are toxic to human.
- chitin synthase is an essential enzyme present only in fungi, a selective antifungal activity may be attained without human toxicity if the activity of the enzyme can be inhibited effectively.
- Most of the compounds of the present invention showed superior inhibitory activities against chitin synthase. Among them, compounds Nos. 7, 8, 17, 18, 39, 40, 49 and 50 showed exceptionally superior inhibitory activities. Also, they showed antifungal activities comparable to that of amphotericin B, which is an antifungal agent used to treat systemic fungal infection. In toxicity test with mice, compound No.
- the compounds in accordance with the present invention have superior inhibitory activities against chitin synthase, antifungal activities comparable to that of amphotericin B, with less toxicity.
Landscapes
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Physics & Mathematics (AREA)
- Electromagnetism (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a berberrubine derivative having superior antifungal activity, more particularly to a berberrubine derivative having inhibitory activity against chitin synthase, which participates in the synthesis of chitin and is essential in the growth of fungi, and having a potent antifungal activity against human pathogenic fungi.
Description
Description BERBERRUBINE DERIVATIVES HAVING ANTIFUNGAL
ACTIVITIES
Technical Field
[1]
[2] The present invention relates to a berberrubine derivative having superior antifungal activity, more particularly to a berberrubine derivative having inhibitory activity against chitin synthase, which participates in the synthesis of chitin and is essential in the growth of fungi, and having potent antifungal activity against human pathogenic fungi, which is represented by the following formula (1):
[3] wherein R is benzyl or substituted benzyl; R is ketone (=O) or OR, wherein R is
C -C alkyl, C -C haloalkyl, C -C hydroxyalkyl, C -C alkenyl, benzyl or
3 10 1 10 1 10 2 10 substituted benzyl; and the substituted benzyl has 1 to 4 substituents selected from halogen atom, C -C alkyl, C -C haloalkyl, C -C alkoxy and C -C haloalkoxy. [4]
Background Art
[5]
[6] Human mycoses can be largely classified into cutaneous mycoses and systemic mycoses and the latter is more of c once rn. Despite the advancement in medical technologies during the past 20 years, the systemic mycoses are on the increase. The mycoses occur frequently in patients whose immune functions have been weakened due to excessive use of antibacterial agents, organ transplantations, long-term medication of anti-cancer medicines, aging, and AIDS, etc., or in patients who rely on catheters or prosthetic devices (Beck-Sague, C. M. et al. J. Infect. Dis., 167, 1247-1251, 1993; Diamond, R. D., Rev. Infect. Dis., 13, 480-486, 1991). Moreover, according to a report, about 40 % of the patients who are hospitalized with infection die of mycoses, with the representative opportunistic pathogens being Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans, etc. (Strenberg, S., Science, 266, 1632-1634, 1994).
[7] The occurrence of invasive candidiasis has increased by ten-fold. The invasive aspergillosis, which frequently occurs in lungs, is the primary cause of death for the bone
marrow-transplanted patients (Pannuti, C. et al., Cancer, 69, 2653-2662, 1992) and the death caused by aspergillosis is on the increase. Thus, the necessity of a new antifungal agent is ever increasing. Since most of the mycoses caused by opportunistic infection are hard to diagnose with the common blood culture, even the treatment of severe immunodeficiency patients is performed depending only on experiences (Walsh, T. J. et al., Rev. Infect. Dis., 13, 496-503, 1991). Most mycoses have been known to occur mainly in patients with weakened immune functions. But, since the earthquake that outbroke in 1994 around Los Angeles (LA), hundreds of mycoses cases had occurred for 3 consecutive years as the spores that had been buried in earth were scattered into the air. During this period, the mortality increased by more than ten times, and with this incidence, it was reported that the fear of mycoses was no longer confined to the patients with weakened immune functions (Strenberg, S., Science, 266, 1632-1634, 1994). The increase of mycoses is gaining the attentions of researchers, yet the prevention of the conditions is not an easy task. In particular, due to the lack of an antifungal agent having superior efficiency with little toxicity, the amphotericin B, which was developed in the 1960s, is still being used in clinical treatment of systemic mycoses in spite of its high toxicity (Georgopadakou, N. H. et al., Science, 264, 371-373, 1994). Moreover, the occurrence of fungal strains resistant to existing antifungal agents is on the increase (Rex, J. H. et al., Antimicrob. Agents Chemother., 39, 1-8, 1995).
[8] Also, the number of cases where a non-pathogenic strain turns into pathogenic strain in patients with weakened immune functions is increasing. Since pathogenic fungi are hard to culture and mostly reproduce asexually, systematic researches on pathogenic fungi have long been deferred (Strenberg, S., Science, 266, 1632-1634, 1994).
[9] At present, the antifungal agents used for clinical purposes are mostly polyenes, azole derivatives, allylamines and thiocarbamates. They either interact with ergosterol, the cell membrane component of fungi, or inhibit the synthesis of ergosterol. However, since most of the compounds have fungistatic activity and the fungi resistant to them appear very frequently, the development of new antifungal agents has been on constant demand. For the treatment of systemic fungal infections, amphotericin B is still widely used because of the lack of superior medicines. However, since it is highly nephrotoxic and may induce pernicious anemia when administered repeatedly, preparation forms developed using lipid complex, colloidal dispersion and liposome to reduce the toxicity were also reported (Kauffman, C. A. et al., Drugs, 53, 539-549, 1997).
[10] Since fungi have cell walls that are different from those of mammals, the cell wall of fungi has long been seen as a good target. The cell wall of fungi maintains the cell structure, prevents the cell from being destroyed by osmosis while participating in the
transfer of macromolecules. The cell wall of fungi is made up of chitin, α-glucan, β- glucan, mannan, etc. Of these, chitin, or β-l,3-glucan, has been the main target for the development of antifungal agents. Chitin is a homopolymer constructed from units of N-acetyl-d-glucosamine linked with β-1,4 glycoside bond. It is an essential component in the cell walls of almost all pathogenic fungi and the skeletal structures of invertebrates. Chitin is synthesized by chitin synthases 1, 2 and 3. Like Saccharomyces cerevisiae, Candida albicans harbours three chitin synthases 1, 2 and 3, which are analogous in terms of structure and function to those of Saccharomyces cerevisiae chitin synthases 2, 1 and 3, respectively. Chitin synthase 1 from Candida albicans participates in septum formation during cell division, while chitin synthase 3 participates in chitin ring formation during the formation of daughter cells from mother cells and the cell wall biogenesis. On the other hand, chitin synthase 2 recovers severely damaged cell wall during cell division (Mio T. et al., J. Bacteriol, 178, 2416-2419, 1996). Among them, chitin synthases 1 and 3 are the main targets for the development of new cell wall biogenesis inhibitors, as they are known as essential enzymes. [11] Berberine, the main component of Coptis chinensis Fr., which has been known as
Huang Lian in Oriental medicine and has been used for the treatment for eye disease, diarrhea or inflammation, is gaining attention because of its antifungal activity. Many researches on berberine derivatives have been reported.
[12] Particularly, berberine derivatives with a variety of functional groups substituted at the C- 13 position have chitin synthase inhibitory effect and antifungal activity (Korean Patent No. 258849; Park K. S., et al., J. Antimicrob. Chemother., 47, 513, 2001).
[13] The compound obtained by pyrolyzing berberine at high temperature to replace the methoxy group at the C-9 position with a hydroxyl group is called berberrubine. As shown below, the hydroxyl group at the C-9 position of berberrubine is present in the form of either a ketone group or a hydroxyl group and is reversibly transformed, as shown in the following formula:
(Berberrubine)
[14] Recently, a berberrubine derivative having improved antifungal activity or DNA- binding affinity by introducing an acyl or alkyl chain at the hydroxyl group of the C-9 position was reported (Kim S. H., Lee S. J., Lee J. Y., Sun W. S., Kim J. H., Planta Medica 03, 277(2002); Pang J. Y., Qin Y., Chen W. H., Luo G. A., Jiang Z. H., Bioorganic & Medicinal Chemistry 13, 5835(2005)). However, the introduction was restricted to the hydroxyl group at the C-9 position of berberrubine and a good antifungal activity was attained only when a hydrocarbon chain longer than 8 carbon atoms was introduced, yet it did not have chitin synthase inhibitory effect. Thus, the antifungal activity could be due to the destruction of cell membrane by the long hydrocarbon chain, and not due to the inhibition of chitin synthase. Such a long hydrocarbon chain renders the development difficult because of its intrinsic toxicity and low hydrophilicity as hydrocarbon.
[15] Korean Patent No. 258,849 discloses that berberine derivatives in which various benzyl groups are introduced at the C- 13 position or at the same time alkoxy groups are introduced at the C-9 and C-IO positions instead of two methoxy groups. In practice, only the berberine derivative represented by the following formula, wherein R 1 and R2 are -O-CH -O- or OCH , R3 is H, R4 is OCH and R5 is benzyl or substituted
2 3 3 J benzyl, is known to have antifungal activity.
[16] However, according to the experiments carried out by the present inventors, the berberrubine derivatives of the present invention, in which methoxy is present at the C- 10 position and a variety of C -C alkoxy are substituted at the C-9 position, showed more potent antifungal activities than those of the substituted berberine derivatives of Korean Patent No. 258,849, in which identical substituents (methoxy) are substituted at the C-9 and C-IO positions (see Table 3 and Table 4 below). For the synthesis of the berberrubine derivatives introduced alkoxy groups at the C-9 position only, berberrubine used as a intermediate was synthesized by pyrolysis.
[17]
Disclosure
[18]
[19] The present inventors worked to synthesize new berberrubine derivatives that can solve the problems of the existing antifungal agents, have selective inhibitory effect against chitin synthase, that are absent in mammals, and have superior antifungal activity.
[20] As a result, they synthesized berberrubine derivatives having a novel structure, in which a variety of functional groups are introduced at the C-9 and C- 13 position positions of berberrubine, and confirmed that these compounds have superior inhibitory activities against chitin synthase and antifungal activities against human pathogenic fungi. In particular, the berberrubine derivatives of the present invention in which both the C-9 and C- 13 positions are substituted by functional groups were confirmed to have more than 5 times of inhibitory activities against chitin synthase and over 16 to 25 times of antifungal activities, when compared with those of the conventional berberine derivatives or berberrubine derivatives.
[21] With improved cell permeability, the novel compounds of the present invention effectively inhibit chitin synthases, and thus have very potent antifungal activity against human pathogenic fungi such as Candida albicans ATCC 10231, Candida lusitaniae ATCC 42720, Candida krusei ATCC 6258, Candida tropicalis ATCC 13803, Candida glabrata ATCC 48435, Candida parapsilosis ATCC 34136, Cryptococcus neoformans ATCC 36556, Aspergillus fumigatus ATCC 16424, Aspergillus flavus ATCC 64025, Aspergillus terreus ATCC 46941, Mucor ramosissimus ATCC 90286, Candida albicans A207(clinical isolate), Trichophyton mentagrophytes ATCC 9533, etc.
[22] Thus, it is an object of the present invention to provide a novel berberrubine derivative having superior antifungal activity.
[23] It is yet another object of the present invention to provide an antifungal agent having superior inhibitory activity against chitin biogenesis of fungi and potent antifungal activity against human pathogenic fungi, which comprises the berberrubine derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
[24] The present invention is characterized by a berberrubine derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof:
(1)
[25] wherein R is benzyl or substituted benzyl; R is ketone (=O) or OR, wherein R is
C -C alkyl, C -C haloalkyl, C -C hydroxyalkyl, C -C alkenyl, benzyl or substituted benzyl; and the substituted benzyl is a substituted benzyl having 1 to 4 sub- stituents selected from halogen atom, C -C alkyl, C -C haloalkyl, C -C alkoxy, and C
1 6 1 6 1 6
-C haloalkoxy.
[26] The present invention is also characterized by an antifungal agent which comprises the berberrubine derivative represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[27] Hereunder is given a more detailed description of the present invention.
[28] The compound of the present invention which is represented by the aforementioned formula (1) can be used in the form of a pharmaceutically acceptable salt, which may be a halide or an acid adduct. More specifically, the pharmaceutically acceptable salt of the compound represented by the aforementioned formula (1) may be selected from fluoride, chloride, bromide, iodide, hydroxide, nitrate, sulfate, acetate, phosphate, tartarate, succinate, lactate, citrate, fumarate, maleate, glycolate, formate, malate, benzoate, methanesulfonate, benzenesulfonate, asparaginate, salicylate, glycerate and ascorbinate.
[29] Also, the compound of the present invention which is represented by the aforementioned formula (1) may be in the form of solvate (e.g., hydrate).
[30] Preferably, in the compound of the present invention which is represented by the formula (1), R is benzyl or substituted benzyl having 1 to 4 substituents selected from halogen, C -C alkyl, C -C haloalkyl, C -C alkoxy and C -C haloalkoxy and R is
1 6 1 6 1 6 1 6 2 ketone (=O) or OR, wherein R is C -C alkyl, C -C haloalkyl, C -C hydroxyalkyl, C
-C alkenyl, benzyl or C -C alkyl substituted benzyl. [31] Examples of the particularly preferable compound of the present invention which is represented by the formula (1) are as follows:
[32] 13-(3,4,5-trifluorobenzyl)berberrubine (Compound No. 1),
[33] 13-(3,4,5-trimethoxybenzyl)berberrubine (Compound No. 2),
[34] 13-(4-trifluoromethoxybenzyl)berberrubine (Compound No. 3),
[35] 13-(4-trifluoromethylbenzyl)berberrubine (Compound No. 4),
[36] 13-(4-tert-butylbenzyl)berberrubine (Compound No. 5),
[37] 13-(4-isopropylbenzyl)berberrubine (Compound No. 6),
[38] 13-(4-tert-butylbenzyl)-9-0-propylberberrubine iodide (Compound No. 7),
[39] 13-(4-tert-butylbenzyl)-9-0-butylberberrubine iodide (Compound No. 8),
[40] 13-(4-tert-butylbenzyl)-9-0-hexylberberrubine iodide (Compound No. 9),
[41] 13-(4-tert-butylbenzyl)-9-O-octylberberrubine iodide (Compound No. 10),
[42] 13-(4-tert-butylbenzyl)-9-O-(3-hydroxypropyl)berberrubine iodide (Compound
No. 11),
[43] 13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberτubine iodide (Compound No.
12),
[44] 13-(4-tert-butylbenzyl)-9-O-allylberbeπubine iodide (Compound No. 13),
[45] 13-(4-tert-butylbenzyl)-9-O-crotylberberrubine bromide (Compound No. 14),
[46] 13-(4-tert-butylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide (Compound
No. 15), [47] 13-(4-tert-butylbenzyl)-9-O-(4-isopropylbenzyl)berbeπubine bromide (Compound
No. 16),
[48] 13-(4-isopropylbenzyl)-9-O-propylberberrubine iodide (Compound No. 17),
[49] 13-(4-isopropylbenzyl)-9-O-butylberberrubine iodide (Compound No. 18),
[50] 13-(4-isopropylbenzyl)-9-O-hexylberbeπubine iodide (Compound No. 19),
[51] 13-(4-isopropylbenzyl)-9-O-octylberberrubine iodide (Compound No. 20),
[52] 13-(4-isopropylbenzyl)-9-O-(3-hydroxypropyl)berberrubine iodide (Compound
No. 21), [53] 13-(4-isopropylbenzyl)-9-O-(6-chlorohexyl)berberrubine iodide (Compound No.
22),
[54] 13-(4-isopropylbenzyl)-9-O-allylberbeπubine iodide (Compound No. 23),
[55] 13-(4-isopropylbenzyl)-9-O-crotylberberrubine bromide (Compound No. 24),
[56] 13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berbeπubine bromide (Compound
No. 25), [57] 13-(4-isopropylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine bromide (Compound
No. 26),
[58] 13-(3,4,5-trifluorobenzyl)-9-O-butylberberrubine iodide (Compound No. 27),
[59] 13-(3,4,5-trifluorobenzyl)-9-O-hexylberbeπubine iodide (Compound No. 28),
[60] 13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 29),
[61] 13-(3,4,5-trimethoxybenzyl)-9-O-butylberberrubine iodide (Compound No. 30),
[62] 13-(3,4,5-trimethoxybenzyl)-9-O-hexylberberrubine iodide (Compound No. 31),
[63] 13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 32),
[64] 13-(4-trifluoromethoxybenzyl)-9-O-butylberberrubine iodide (Compound No. 33),
[65] 13-(4-trifluoromethoxybenzyl)-9-O-hexylberberrubine iodide (Compound No. 34),
[66] 13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 35),
[67] 13-(4-trifluoromethylbenzyl)-9-O-butylberberrubine iodide (Compound No. 36),
[68] 13-(4-trifluoromethylbenzyl)-9-O-hexylberberrubine iodide (Compound No. 37),
[69] 13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 38),
[70] 13-(4-tert-butylbenzyl)-9-0-propylberberrubine chloride (Compound No. 39),
[71] 13-(4-tert-butylbenzyl)-9-O-butylberberrubine chloride (Compound No. 40),
[72] 13-(4-tert-butylbenzyl)-9-O-hexylberbeπubine chloride (Compound No. 41),
[73] 13-(4-tert-butylbenzyl)-9-O-octylberberrubine chloride (Compound No. 42),
[74] 13-(4-tert-butylbenzyl)-9-O-(3-hydroxypropyl)berbeπubine chloride (Compound
No. 43), [75] 13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberrubine chloride (Compound No.
44),
[76] 13-(4-tert-butylbenzyl)-9-O-allylberbeπubine chloride (Compound No. 45),
[77] 13-(4-tert-butylbenzyl)-9-O-crotylberberrubine chloride (Compound No. 46),
[78] 13-(4-tert-butylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride (Compound
No. 47), [79] 13-(4-tert-butylbenzyl)-9-O-(4-isopropylbenzyl)berbeπubine chloride (Compound
No. 48),
[80] 13-(4-isopropylbenzyl)-9-O-propylberberrubine chloride (Compound No. 49),
[81] 13-(4-isopropylbenzyl)-9-O-butylberberrubine chloride (Compound No. 50),
[82] 13-(4-isopropylbenzyl)-9-O-hexylberbeπubine chloride (Compound No. 51),
[83] 13-(4-isopropylbenzyl)-9-O-octylberberrubine chloride (Compound No. 52),
[84] 13-(4-isopropylbenzyl)-9-O-(3-hydroxypropyl)berberrubine chloride (Compound
No. 53), [85] 13-(4-isopropylbenzyl)-9-O-(6-chlorohexyl)berberrubine chloride (Compound No.
54),
[86] 13-(4-isopropylbenzyl)-9-O-allylberberrubine chloride (Compound No. 55),
[87] 13-(4-isopropylbenzyl)-9-O-crotylberberrubine chloride (Compound No. 56),
[88] 13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berberτubine chloride (Compound
No. 57), [89] 13-(4-isopropylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine chloride (Compound
No. 58),
[90] 13-(3,4,5-trifluorobenzyl)-9-O-butylberberrubine chloride (Compound No. 59),
[91] 13-(3,4,5-trifluorobenzyl)-9-O-hexylberbeπubine chloride (Compound No. 60),
[92] 13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 61),
[93] 13-(3,4,5-trimethoxybenzyl)-9-O-butylberberrubine chloride (Compound No. 62),
[94] 13-(3,4,5-trimethoxybenzyl)-9-O-hexylberberrubine chloride (Compound No. 63),
[95] 13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 64), [96] 13-(4-trifluoromethoxybenzyl)-9-O-butylberberrubine chloride (Compound No.
65),
[97] 13-(4-trifluoromethoxybenzyl)-9-O-hexylberberrubine chloride (Compound No.
66),
[98] 13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 67),
[99] 13-(4-trifluoromethylbenzyl)-9-O-butylberberrubine chloride (Compound No. 68),
[100] 13-(4-trifluoromethylbenzyl)-9-0-hexylberberrubine chloride (Compound No. 69),
[101] 13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 70) and pharmaceutically acceptable salts thereof.
[102] The novel compound in accordance with the present invention has superior inhibitory activity against chitin synthase (chitin synthase 1), which participates in chitin biogenesis, and potent antifungal activity against human pathogenic fungi. The present invention also provides a pharmaceutical composition comprising the compound represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[103] The pharmaceutical composition of the present invention comprises the compound represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable excipient.
[104] The pharmaceutical composition of the present invention may be prepared into: oral administration form including tablet, capsule and syrup; injection form; suppository form; external application form including ointment, cream, lotion and liquid; etc.
[105] The present invention also provides a method for the prevention and the treatment of systemic infection by fungi in mammals by administering an effective dosage of the compound, represented by the aforementioned formula (1) or a pharmaceutically acceptable salt thereof.
[106] The compound of the present invention can be orally administered in the form of a tablet, a capsule (sustained release or controlled release), a pill, powder, a granule, an elixir, a tincture, a suspension, a syrup or an emulsion. Also, it can be administered by the method well known by those skilled in the art, e.g., intravenously, intraperitoneally, locally (e.g., eye drops), subcutaneously, intramuscularly, transdermally (e.g., patches), etc.
[107] The dosage of the compound of the present invention is determined by considering age, weight, sex, physical conditions, etc. of a patient, seriousness of the conditions to be treated, administration route, liver or lung function of the patient, the particular compound or the salt to be used, etc. An average doctor, veterinarian or clinician may easily determine the pharmaceutically effective dosage required for the prevention or inhibition of the development of the condition.
[108] The oral dosage for attaining the purpose of the present invention is about 0.01-100
mg/kg/day, preferably about 0.01-10 mg/kg/day, and more preferably about 0.1-5.0 mg/kg/day. For oral administration, it is preferable that the composition is provided in the form of tablet comprising the active ingredient in 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 mg in order to find the adequate dosage for the particular patient. Typically, a drug comprises the active ingredient in the range from about 0.01 mg to about 500 mg, preferably from about 1 mg to about 100 mg. In case of an intravenous injection, the most preferred dosage is 0.1-10 mg/kg/min. The compound of the present invention may be administered once, twice, three times or four times daily. Also, preferably, the compound of the present invention may be administered either intranasally using an adequate intranasal carrier or transdermally using a commonly used transdermal patch. It is obvious that the transdermal administration ensures a continuous administration.
[109] The compound of the present invention, or the active ingredient, may be mixed with a pharmaceutically acceptable diluent or excipient (collectively, the 'excipient'), which is selected considering the type of administration.
[110] For example, in case of oral administration using tablet or capsule, the active ingredient may be mixed with non-toxic, pharmaceutically acceptable excipient, such as lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, calcium phosphate dibasic, calcium sulfate, mannitol, sorbitol, etc. In case of liquid type oral administration, the active ingredient may be mixed with non-toxic, pharmaceutically acceptable excipient such as ethanol, glycerol, water, etc. If required, an adequate binder, lubricant, dispersant or colorant may be added to the mixture solution. The binder may be natural sugars such as starch, gelatin, glucose and β-lactose, natural or synthetic rubbers such as corn sweetener, acacia and sodium alginate, carboxymethyl- cellulose, polyethylene glycol, wax, etc. The lubricant may be sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. And, the dispersant may be starch, methylcellulose, agar, bentonite, xanthan rubber, etc.
[Ill] The method for preparing the novel compound of the present invention represented by the aforementioned formula (1) can be schematically illustrated by the following Scheme 1.
Scheme 1
[112] In Scheme 1, R and R are the same as defined above, X is a halide ion or an acid anion derived from an organic or inorganic acid. [113] First, an acetonyl group is introduced at the C-8 position of the berberine salt represented by the aforementioned formula (2) to obtain the
8-acetonyldihydroberberine represented by the aforementioned formula (3). Then, an electrophilic alkyl substituent (R -X, where X is a halogen atom) is used to synthesize the compound represented by the aforementioned formula (4), wherein the functional group R is introduced at the C- 13 position. The resultant compound represented by the aforementioned formula (4) is pyrolyzed at high temperature to obtain the berberrubine derivative represented by the aforementioned formula (Ia), wherein a hydroxyl group is introduced at the C-9 position. The resultant berberrubine derivative represented by the aforementioned formula (Ia) is reversibly converted to the berberrubine derivative represented by the aforementioned formula (Ib), wherein a ketone (O=) is introduced at the C-9 position. Furthermore, in order to introduce various functional groups R at the C-9 position, an electrophilic alkyl substituent (R-X, where X is halogen atom) is
reacted with the compound represented by the formula (Ia) or (Ib) to attain the novel compound represented by the aforementioned formula (Ic), wherein both C-9 and C- 13 positions are substituted by the functional groups.
[114] In Scheme 1, the introduction of the acetonyl group at the C-8 position of the berberine salt represented by the aforementioned formula (2) is carried out using acetone and, if necessary, a suitable organic solvent and a commonly used organic or inorganic base may be added.
[115] And, the introduction of the functional group at the C- 13 position of the
8-acetonyldihydroberberine represented by the aforementioned formula (3) and the introduction of the functional group R at the C-9 position of the berberrubine derivative represented by the aforementioned formula (Ia) are carried out, respectively, using an adequate electrophilic alkyl substituent. During the reaction with the electrophilic alkyl substituent, a suitable organic solvent and a commonly used organic or inorganic base may be added, if necessary.
[116] And, the pyrolysis of the compound represented by the aforementioned formula (4) for substituting the methoxy group at the C-9 position with the hydroxyl group is performed at 170-190 °C.
[117] In the preparation in accordance with the present invention, a commonly used organic solvent selected from methylene chloride, chloroform, acetonitrile, dimethyl- formamide, tetrahydrofuran, etc., may be used as the reaction solvent. For the base, organic bases such as amine or inorganic bases such as alkali metal hydride, hydroxide, carbonate, etc., may be used. Specifically, the base may be selected from ammonia, triethylamine, sodium hydride, potassium hydride, lithium hydride, potassium carbonate, or sodium carbonate, etc.
[118] The reaction intermediate or the target compound represented by the aforementioned formula (1) obtained by the preparation process may be separated and purified by the commonly utilized method, such as chromatography and recrys- tallization.
[119]
Best Mode
[120]
[121] Practical and preferred embodiments of the present invention are illustrated as shown in the following examples. However, it will be appreciated that those skilled in the art may, in consideration of this disclosure, make modifications and improvements within the spirit and scope of the present invention.
[122]
[123] Example 1: 13 -(3,4,5-Trifluorobenzyl)berberrubine (Compound No. 1)
[124] 55 mL of 5 N NaOH solution was added to 10 g of berberine chloride. 8 mL of
acetone was slowly added while vigorously stirring the solution. The reaction was performed at room temperature for 1 hour. The reaction solution was filtered, sufficiently washed with 80 % methanol and dried to obtain 9.2 g of 8-acetonyldihydroberberine. 1.8 g of 8-acetonyldihydroberberine was dissolved in 60 mL of acetonitrile (CH CN). Then, 0.42 g of sodium iodide (NaI) and 1.4 mL of 3,4,5-trifluorobenzyl bromide were added and the reaction was performed at 80 °C for 4 hours. The reaction solution was concentrated under reduced pressure and then washed with ethyl ether. 1.1 g of 13-(3,4,5-trifluoro)berberine was obtained from silica gel column chromatography. During the chromatography, a 1:20 organic solvent mixture of methanol and chloroform was used as an eluent.
[125] 1 g of 13-(3,4,5-trifluoro)berberine was dissolved in DMF. After vigorously stirring at 190 °C for 2 hours, the reaction solution was concentrated under reduced pressure. 0.56 g of 13-(3,4,5-trifluoro)berberrubine was obtained from chromatography using silica gel and a 1:9 solvent mixture of methanol and chloroform.
[126] λ H-NMR (DMSO-J 300 MHz) δ 9.42 (s, IH), 7.61 (s, IH), 7.31 (s, IH), 7.12 (d,
IH), 6.79 (d, 2H), 6.24 (d, IH), 5.98(s, 2H), 4.49 (s, 2H), 4.42 (broad s, 2H), 3.87 (s, 3H) 3.04 (t, 2H).
[127]
[128] Example 2: 13 -(3,4,5-Trimethoxybenzyl)berberrubine (Compound No. 2)
[129] 0.61 g of 13-(3,4,5-trimethoxybenzyl)berberrubine was obtained in the same manner as in the aforementioned Example 1, except that 3,4,5-trimethoxybenzyl bromide was used instead of 3,4,5-trifluorobenzyl bromide.
[130] λ H-NMR (DMSO-J 300 MHz) δ 9.46 (s, IH), 7.63 (s, IH), 7.32 (s, IH), 7.13 (d,
IH), 6.77 (d, 2H), 6.22 (d, IH), 5.99(s, 2H), 4.51 (s, 2H), 4.44 (broad s, 2H), 4.04 (s, 3H), 3.91 (s, 6H), 3.87 (s, 3H) 3.04 (t, 2H).
[131]
[132] Example 3: 13-(4-Trifluoromethoxybenzyl)berberrubine (Compound No. 3)
[133] 0.48 g of 13-(4-trifluoromethoxybenzyl)berberrubine was obtained in the same manner as in the aforementioned Example 1, except that 4-trifluoromethoxybenzyl bromide was used instead of 3,4,5-trifluorobenzyl bromide.
[134] λ H-NMR (DMSO-J 300 MHz) δ : 9.48 (s, IH), 7.45 (d, IH), 7.31 (s, IH), 7.18
(d, IH), 7.08 (s, IH), 7.06 (s, IH), 6.87 (s, IH), 6.85 (s, IH), 6.46 (d, IH), 5.97 (s, 2H), 4.43 (t, 2H), 4.41 (s, 2H), 3.89 (s, 3H) 3.02 (t, 2H).
[135]
[136] Example 4: 13-(4-Trifluoromethylbenzyl)berberrubine (Compound No. 4)
[137] 0.43 g of 13-(4-trifluoromethylbenzyl)berberrubine was obtained in the same manner as in the aforementioned Example 1, except that 4-trifluoromethylbenzyl bromide was used instead of 3,4,5-trifluorobenzyl bromide.
[138] λ H-NMR (DMSO-J6, 300 MHz) δ 9.42 (s, IH), 7.61 (s, IH), 7.58 (s, IH), 7.31 (s,
IH), 7.29 (s, IH), 7.12 (d, IH), 6.79 (d, 2H), 6.24 (d, IH), 5.98 (s, 2H), 4.49 (s, 2H), 4.42 (broad s, 2H), 3.87 (s, 3H) 3.04 (t, 2H).
[139]
[140] Example 5: 13-(4-i'e/t-Butylbenzyl)berberrubine (Compound No. 5)
[141] 0.63 g of 13-(4-tert-butylbenzyl)berberrubine was obtained in the same manner as in the aforementioned Example 1, except that 4-terf-butylbenzyl bromide was used instead of 3,4,5-trifluorobenzyl bromide.
[142] λ H-NMR (DMSO-J 300 MHz) δ 9.5 (s, IH), 7.34 (s, IH), 7.31 (s, IH), 7.18 (d,
IH), 7.08 (s, IH), 7.06 (s, IH), 6.98 (s, IH), 6.78 (s, IH), 6.43 (d, IH), 5.97 (s, 2H), 4.42 (t, 2H), 4.40 (s, 2H), 3.88 (s, 3H) 3.03 (t, 2H) 1.31 (s, 9H).
[143]
[144] Example 6: 13-(4-Isopropylbenzyl)berberrubine (Compound No. 6)
[145] 0.65 g of 13-(4-isopropylbenzyl)berberrubine was obtained in the same manner as in the aforementioned Example 1, except that 4-isopropylbenzyl bromide was used instead of 3,4,5-trifluorobenzyl bromide.
[146] λ H-NMR (DMSO-J 300 MHz) δ 9.51 (s, IH), 7.35 (s, IH), 7.34 (s, IH), 7.16 (d,
IH), 7.06 (s, IH), 7.02 (s, IH), 6.97 (s, IH), 6.76 (s, IH), 6.41 (d, IH), 5.98 (s, 2H), 4.44 (t, 2H), 4.42 (s, 2H), 3.87 (s, 3H) 3.05 (t, 2H) 2.82 (m, IH), 1.33 (d, 6H).
[147]
[148] Example 7: 13 -(4-i'e/t-Butylbenzyl)-9-0-propylberberrubine iodide
(Compound No. 7)
[149] 0.5 g of 13-(4-tert-butylbenzyl)berberrubine obtained in the aforementioned
Example 5 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.25 mL of propyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.32 g of 13-(4-tert-butylbenzyl)-9-0- propylber- berrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl3).
[150] 1H-NMR (DMSO-J 300 MHz) δ 10.27 (s, IH), 7.63 (m, 2H), 7.32 (d, 2H), 7.02
(s, IH), 6.96 (s, 2H), 6.84 (s, IH), 5.96 (s, 2H), 5.36 (broad t, 2H), 4.63 (s, 2H), 4.54 (t, 2H) 4.02 (s, 3H) 3.31 (t, 2H) 2.04 (m, 2H), 1.35 (s, 9H), 1.04 (t, 3H).
[151]
[152] Example 8: 13 -(4-te/f-Butylbenzyl)-9-0-butylberberrubine iodide
(Compound No. 8)
[153] 0.33 g of 13-(4-tert-butylbenzyl)-9-0-butylberberrubine iodide was obtained in the same manner as in the aforementioned Example 7, except that butyl iodide was used instead of propyl iodide.
[154] λ H-NMR (DMSO-J 300 MHz) δ 10.27 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.87 (s, IH), 5.99 (s, 2H), 5.38 (broad t, 2H), 4.62 (s, 2H), 4.57 (t,
2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.32 (s, 9H), 1.03 (t, 3H). [155] [156] Example 9: 13 -(4-te/t-Butylbenzyl)-9-0-hexylberberrubine iodide
(Compound No. 9) [157] 0.35 g of 13-(4-tert-butylbenzyl)-9-0-hexylberberrubine iodide was obtained in the same manner as in the aforementioned Example 7, except that hexyl iodide was used instead of propyl iodide. [158] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.67 (m, 2H), 7.38 (d, 2H), 7.04
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t,
2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.43-1.79 (m, 6H), 1.31 (s, 9H), 1.05 (t,
3H). [159] [160] Example 10: 13 -(4-te/f-Butylbenzyl)-9-0-octylberberrubine iodide
(Compound No. 10) [161] 0.32 g of 13-(4-terf-butylbenzyl)-9-O-octylberberrubine iodide was obtained in the same manner as in the aforementioned Example 7, except that octyl iodide was used instead of propyl iodide. [162] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.28 (s, IH), 7.69 (m, 2H), 7.40 (d, 2H), 7.07
(s, IH), 6.95 (s, 2H), 6.88 (s, IH), 5.98 (s, 2H), 5.35 (broad t, 2H), 4.64 (s, 2H), 4.54 (t,
2H) 4.04 (s, 3H) 3.25 (t, 2H) 2.06 (m, 2H), 1.44-1.80 (m, 10H), 1.33 (s, 9H), 1.03 (t,
3H). [163] [164] Example 11: 13-(4-l'e/t-Butylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide (Compound No. 11) [165] 0.23 g of 13-(4-terf-butylbenzyl)-9-O-(3-hydroxypropyl)berberrubine iodide was obtained in the same manner as in the aforementioned Example 7, except that l-iodo-3-propanol was used instead of propyl iodide. [166] λ H-NMR (DMSO-J 300 MHz) δ 10.56 (s, IH), 7.65 (m, 2H), 7.37 (d, 2H), 7.03
(s, IH), 7.00 (s, 2H), 6.87 (s, IH), 6.00 (s, 2H), 5.20 (broad t, 2H), 4.69 (t, 2H), 4.63 (s,
2H), 4.05(t, 2H), 4.02 (s, 3H) 3.28 (t, 2H) 2.25 (m, 2H), 1.32 (s, 9H). [167] [168] Example 12: 13-(4-i'e/t-Butylbenzyl)-9-0-(6-chlorohexyl)berberrubine iodide
(Compound No. 12) [169] 0.27 g of 13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberrubine iodide was obtained in the same manner as in the aforementioned Example 7, except that l-chloro-6-iodohexane was used instead of propyl iodide.
[170] λ H-NMR (DMSO-J 300 MHz) δ 10.30 (s, IH), 7.66 (m, 2H), 7.35 (d, 2H), 7.02
(d, 2H), 7.00 (s, IH), 6.87 (s, IH), 6.00 (s, 2H), 5.21 (broad t, 2H), 4.63 (s, 2H), 4.61
(t, 2H), 4.01 (s, 3H), 3.60 (t 2H), 3.30 (t, 2H) 2.10 (m, 2H), 1.89 (m, 2H), 1.58-1.64
(m, 4H), 1.32 (s, 9H). [171] [172] Example 13: 13 -(4-te/*-Butylbenzyl)-9-0-allylberberrubine iodide
(Compound No. 13) [173] 0.24 g of 13-(4-tert-butylbenzyl)-9-O-allylberberrubine iodide was obtained in the same manner as in the aforementioned Example 7, except that allyl iodide was used instead of propyl iodide. [174] λ H-NMR (DMSO-J 300 MHz) δ 10.55 (s, IH), 7.65 (m, 2H), 7.36 (d, 2H), 7.03
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.49(m, IH), 6.00 (s, 2H), 5.5 (dd, IH), 5.33 (dd,
IH), 5.13 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.29 (t, 2H), 1.32 (s, 9H). [175] [176] Example 14: 13 -(4-i'e/t-Butylbenzyl)-9-0-crotylberberrubine bromide
(Compound No. 14) [177] 0.22 g of 13-(4-tert-butylbenzyl)-9-O-crotylberberrubine bromide was obtained in the same manner as in the aforementioned Example 7, except that crotyl bromide was used instead of propyl iodide. [178] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.52 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.12(m, 2H), 6.00 (s, 2H), 5.31 (broad, 2H), 5.06 (d,
2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.30 (t, 2H), 1.77 (d, 3H), 1.32 (s, 9H). [179] [180] Example 15: 13-(4-te/t-Butylbenzyl)-9-O-(4-te/t-butylbenzyl)berberrubine bromide (Compound No. 15) [181] 0.38 g of 13-(4-terf-butylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 7, except that 4- terf-butylbenzyl bromide was used instead of propyl iodide. [182] λ H-NMR (DMSO-J 300 MHz) δ 10.34 (s, IH), 7.77 (d, 2H), 7.66 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.62 (s, 2H),
5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 1.34 (s, 9H), 1.32 (s, 9H). [183] [184] Example 16: 13-(4-l'e/t-Butylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine bromide (Compound No. 16) [ 185] 0.34 g of 13-(4-terf-butylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 7, except that
4-isopropylbenzyl bromide was used instead of propyl iodide. [186] λ H-NMR (DMSO-J 6 , 300 MHz) δ 10.38 (s, IH), 7.77 (d, 2H), 7.67 (m, 2H), 7.36
(d, 2H), 7.28(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.99 (s, 2H), 5.63 (s, 2H), 5.20 (broad t, 2H), 4.62 (s, 2H), 4.04 (s, 3H), 3.30 (t, 2H), 2.91 (m, IH), 1.32 (s, 9H), 1.24 (d, 6H).
[187]
[188] Example 17: 13 -(4-Isopropylbenzyl)-9-0-propylberberrubine iodide
(Compound No. 17)
[189] 0.5 g of 13-(4-isopropylbenzyl)berberrubine obtained in the aforementioned
Example 6 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.25 mL of propyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.33 g of 13-(4-isopropylbenzyl)-9-O- propylber- berrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl3).
[190] λ H-NMR (DMSO-J 6> 300 MHz) δ 10.26 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.01
(s, IH), 6.96 (s, 2H), 6.83 (s, IH), 5.96 (s, 2H), 5.32 (broad t, 2H), 4.64 (s, 2H), 4.53 (t, 2H), 4.02 (s, 3H), 3.32 (t, 2H), 2.91 (m, IH), 2.04 (m, 2H), 1.25 (d, 6H), 1.04 (t, 3H).
[191]
[192] Example 18: 13 -(4-Isopropylbenzyl)-9-0-butylberberrubine iodide
(Compound No. 18)
[193] 0.31 g of 13-(4-isopropylbenzyl)-9-O-butylberberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that butyl iodide was used instead of propyl iodide.
[194] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.63 (m, 2H), 7.36 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.87 (s, IH), 5.99 (s, 2H), 5.38 (broad t, 2H), 4.64 (s, 2H), 4.52 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.91 (m, IH), 2.07 (m, 2H), 1.63 (m, 2H), 1.26 (d, 6H), 1.04 (t, 3H).
[195]
[196] Example 19: 13 -(4-Isopropylbenzyl)-9-0-hexylberberrubine iodide
(Compound No. 19)
[197] 0.32 g of 13-(4-isopropylbenzyl)-9-O-hexylberberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that hexyl iodide was used instead of propyl iodide.
[198] λ H-NMR (DMSO-J 300 MHz) δ 10.32 (s, IH), 7.67 (m, 2H), 7.36 (d, 2H), 7.04
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.91 (m, IH), 2.04 (m, 2H), 1.43-1.78 (m, 6H), 1.25 (d, 6H), 1.05 (t, 3H).
[199]
[200] Example 20: 13 -(4-Isopropylbenzyl)-9-0-octylberberrubine iodide
(Compound No. 20)
[201] 0.32 g of 13-(4-isopropylbenzyl)-9-0-octylberberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that octyl iodide was used instead of propyl iodide. [202] λ H-NMR (DMSO-J 300 MHz) δ 10.28 (s, IH), 7.69 (m, 2H), 7.40 (d, 2H), 7.07
(s, IH), 6.95 (s, 2H), 6.88 (s, IH), 5.98 (s, 2H), 5.35 (broad t, 2H), 4.64 (s, 2H), 4.54 (t,
2H) 4.04 (s, 3H) 3.25 (t, 2H) 2.92 (m, IH), 2.06 (m, 2H), 1.44-1.81 (m, 10H), 1.27 (d,
6H), 1.03 (t, 3H). [203] [204] Example 21: 13-(4-Isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide (Compound No. 21) [205] 0.25 g of 13-(4-isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that l-iodo-3-propanol was used instead of propyl iodide. [206] λ H-NMR (DMSO-J 300 MHz) δ 10.26 (s, IH), 7.65 (m, 2H), 7.37 (d, 2H), 7.03
(s, IH), 7.00 (s, 2H), 6.87 (s, IH), 6.00 (s, 2H), 5.20 (broad t, 2H), 4.69 (t, 2H), 4.63 (s,
2H), 4.05(t, 2H), 4.02 (s, 3H), 3.28 (t, 2H), 2.90 (m, IH), 2.25 (m, 2H), 1.27 (d, 6H). [207] [208] Example 22: 13-(4-Isopropylbenzyl)-9-0-(6-chlorohexyl)berberrubine iodide
(Compound No. 22) [209] 0.29 g of 13-(4-isopropylbenzyl)-9-O-(6-chlorohexyl)berberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that l-chloro-6-iodohexane was used instead of propyl iodide. [210] λ H-NMR (DMSO-J 300 MHz) δ 10.30 (s, IH), 7.66 (m, 2H), 7.35 (d, 2H), 7.02
(d, 2H), 7.00 (s, IH), 6.87 (s, IH), 6.00 (s, 2H), 5.21 (broad t, 2H), 4.63 (s, 2H), 4.61
(t, 2H), 4.01 (s, 3H), 3.60 (t 2H), 3.30 (t, 2H), 2.91 (m, IH), 2.10 (m, 2H), 1.89 (m,
2H), 1.58-1.64 (m, 4H), 1.28 (d, 6H). [211] [212] Example 23: 13 -(4-Isopropylbenzyl)-9-0-allylberberrubine iodide
(Compound No. 23) [213] 0.26 g of 13-(4-isopropylbenzyl)-9-O-allylberberrubine iodide was obtained in the same manner as in the aforementioned Example 17, except that allyl iodide was used instead of propyl iodide. [214] λ H-NMR (DMSO-J 300 MHz) δ 10.25 (s, IH), 7.65 (m, 2H), 7.36 (d, 2H), 7.03
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.49(m, IH), 6.00 (s, 2H), 5.5 (dd, IH), 5.33 (dd,
IH), 5.13 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.29 (t, 2H), 2.92 (m, IH), 1.26 (d, 6H). [215] [216] Example 24: 13-(4-Isopropylbenzyl)-9-0-crotylberberrubine bromide
(Compound No. 24)
[217] 0.25 g of 13-(4-isopropylbenzyl)-9-0-crotylberberrubine bromide was obtained in the same manner as in the aforementioned Example 17, except that crotyl bromide was used instead of propyl iodide.
[218] λ H-NMR (DMSO-J 300 MHz) δ 10.30 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.12(m, 2H), 6.00 (s, 2H), 5.31 (broad, 2H), 5.06 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.30 (t, 2H), 2.91 (m, IH), 1.77 (d, 3H), 1.26 (d, 6H).
[219]
[220] Example 25: 13-(4-Isopropylbenzyl)-9-0-(4-te/t-butylbenzyl)berberrubine bromide (Compound No. 25)
[221] 0.37 g of 13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 17, except that A- terf-butylbenzyl bromide was used instead of propyl iodide.
[222] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.34 (s, IH), 7.77 (d, 2H), 7.66 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 2.91 (m, IH), 1.32 (s, 9H), 1.26 (d, 6H).
[223]
[224] Example 26: 13-(4-Isopropylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine bromide (Compound No. 26)
[225] 0.36 g of 13-(4-isopropylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 17, except that 4-isopropylbenzyl bromide was used instead of propyl iodide.
[226] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.78 (d, 2H), 7.67 (m, 2H), 7.36
(d, 2H), 7.28(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.85 (s, IH), 5.99 (s, 2H), 5.63 (s, 2H), 5.20 (broad t, 2H), 4.62 (s, 2H), 4.04 (s, 3H), 3.30 (t, 2H) 2.91 (m, 2H), 1.27 (d, 6H), 1.24 (d, 6H).
[227]
[228] Example 27: 13-(3,4,5-Trifluorobenzyl)-9-0-butylberberrubine iodide
(Compound No. 27)
[229] 0.2 g of 13-(3,4,5-trifluorobenzyl)berberrubine obtained in the aforementioned
Example 1 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(3,4,5-trifluorobenzyl)-9-O-butylberberrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl ).
[230] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.26 (s, IH), 7.64 (s, IH), 7.36 (s, IH), 7.01
(s, IH), 6.96 (s, 2H), 6.83 (s, IH), 5.96 (s, 2H), 5.34 (broad t, 2H), 4.63 (s, 2H), 4.52 (t,
2H), 4.01 (s, 3H), 3.33 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.04 (t, 3H). [231] [232] Example 28: 13-(3,4,5-Trifluorobenzyl)-9-0-hexylberberrubine iodide
(Compound No. 28)
[233] 0.09 g of 13-(3,4,5-trifluorobenzyl)-9-0-hexylberberrubine iodide was obtained in the same manner as in the aforementioned Example 27, except that hexyl iodide was used instead of butyl iodide.
[234] λ H-NMR (DMSO-J 300 MHz) δ 10.32 (s, IH), 7.62 (s, IH), 7.34 (s, IH), 7.01
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.43-1.78 (m, 6H), 1.05 (t, 3H).
[235]
[236] Example 29: 13-(3,4,5-Trifluorobenzyl)-9-0-(4-te/t-butylbenzyl)berberrubine bromide (Compound No. 29)
[237] 0.1 g of 13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 27, except that 4- terf-butylbenzyl bromide was used instead of butyl iodide.
[238] λ H-NMR (DMSO-J 300 MHz) δ 10.32 (s, IH), 7.77 (d, 2H), 7.62 (m, 2H), 7.34
(s, IH), 7.01 (s, 2H), 6.93 (s, 2H), 6.86 (s, IH), 5.98 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.63 (s, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 1.32 (s, 9H).
[239]
[240] Example 30: 13-(3,4,5-trimethoxybenzyl)-9-0-butylberberrubine iodide
(Compound No. 30)
[241] 0.2 g of 13-(3,4,5-trimethoxybenzyl)berberrubine obtained in the aforementioned
Example 2 was dissolved in 50 mL of acetonitrile (CH CN). After completely the mixture dissolving by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(3,4,5-trimethoxybenzyl)-9-O-butylberberrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl ).
[242] λ H-NMR (DMSO-J 300 MHz) δ 10.28 (s, IH), 7.65 (s, IH), 7.36 (s, IH), 7.03
(s, IH), 6.96 (s, 2H), 6.83 (s, IH), 5.96 (s, 2H), 5.28 (broad t, 2H), 4.62 (s, 2H), 4.52 (t, 2H), 4.05(s, 6H), 4.03 (s, 3H), 3.33 (t, 2H), 2.07 (m, 2H), 1.64 (m, 2H), 1.03 (t, 3H).
[243]
[244] Example 31: 13-(3,4,5-Trimethoxybenzyl)-9-0-hexylberberrubine iodide
(Compound No. 31)
[245] 0.09 g of 13-(3,4,5-trimethoxybenzyl)-9-O-hexylberberrubine iodide was obtained in the same manner as in the aforementioned Example 30, except that hexyl iodide was used instead of butyl iodide.
[246] λ H-NMR (DMSO-J 6 , 300 MHz) δ 10.31 (s, IH), 7.64 (s, IH), 7.33 (s, IH), 7.03
(s, IH), 6.92 (s, 2H), 6.85 (s, IH), 5.97 (s, 2H), 5.32 (broad t, 2H), 4.63 (s, 2H), 4.56 (t, 2H), 4.04(s, 6H), 4.02 (s, 3H), 3.24 (t, 2H), 2.05 (m, 2H), 1.41-1.79 (m, 6H), 1.05 (t, 3H).
[247]
[248] Example 32: 13-(3,4,5-Trimethoxybenzyl)-9-0-(4-te/t - butylbenzyl)berberrubine bromide (Compound No. 32)
[249] 0.1 g of 13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 30, except that 4-tert-butylbenzyl bromide was used instead of butyl iodide.
[250] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.76 (d, 2H), 7.63 (m, 2H), 7.34
(s, IH), 7.01 (s, 2H), 6.93 (s, 2H), 6.86 (s, IH), 5.98 (s, 2H), 5.61 (s, 2H), 5.22 (broad t, 2H), 4.65 (s, 2H), 4.04(s, 6H), 4.02 (s, 3H), 3.24 (t, 2H), 1.33 (s, 9H).
[251]
[252] Example 33: 13-(4-Trifluoromethoxybenzyl)-9-0-butylberberrubine iodide
(Compound No. 33)
[253] 0.2 g of 13-(4-trifluoromethoxybenzyl)berberrubine obtained in the aforementioned
Example 3 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(4-trifluoromethoxybenzyl)-9-0- butylber- berrubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl3).
[254] λ H-NMR (DMSO-J 300 MHz) δ 10.27 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.87 (s, IH), 5.99 (s, 2H), 5.38 (broad t, 2H), 4.62 (s, 2H), 4.57 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.03 (t, 3H).
[255]
[256] Example 34: 13-(4-Trifluoromethoxybenzyl)-9-0-hexylberberrubine iodide
(Compound No. 34)
[257] 0.09 g of 13-(4-trifluoromethoxybenzyl)-9-O-hexylberberrubine iodide was obtained in the same manner as in the aforementioned Example 33, except that hexyl iodide was used instead of butyl iodide.
[258] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.67 (m, 2H), 7.38 (d, 2H), 7.04
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.43-1.79 (m, 6H), 1.05 (t, 3H).
[259]
[260] Example 35: 13-(4-Trifluoromethoxybenzyl)-9-0-(4-te/t - butylbenzyl)berberrubine bromide (Compound No. 35)
[261] 0.1 g of 13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine
bromide was obtained in the same manner as in the aforementioned Example 33, except that 4-tert-butylbenzyl bromide was used instead of butyl iodide.
[262] λ H-NMR (DMSO-J 300 MHz) δ 10.34 (s, IH), 7.77 (d, 2H), 7.66 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 1.32 (s, 9H).
[263]
[264] Example 36: 13-(4-Trifluoromethylbenzyl)-9-0-butylberberrubine iodide
(Compound No. 36)
[265] 0.2 g of 13-(4-trifluoromethylbenzyl)berbeπubine obtained in the aforementioned
Example 4 was dissolved in 50 mL of acetonitrile (CH CN). After completely dissolving the mixture by string at 120 °C, a reaction was performed for 4 hours by slowly adding 0.1 mL of butyl iodide dropwise. The reaction solution was concentrated under reduced pressure. 0.08 g of 13-(4-trifluoromethylbenzyl)-9-O-butylberbeπubine iodide was obtained from silica gel column chromatography (1 : 9/MeOH : CHCl ).
[266] λ H-NMR (DMSO-J 300 MHz) δ 10.25 (s, IH), 7.64 (m, 2H), 7.35 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.85 (s, IH), 5.99 (s, 2H), 5.35 (broad t, 2H), 4.62 (s, 2H), 4.57 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.03 (t, 3H).
[267]
[268] Example 37: 13-(4-Trifluoromethylbenzyl)-9-0-hexylberberrubine iodide
(Compound No. 37)
[269] 0.09 g of 13-(4-trifluoromethylbenzyl)-9-0-hexylberberrubine iodide was obtained in the same manner as in the aforementioned Example 36, except that hexyl iodide was used instead of butyl iodide.
[270] λ H-NMR (DMSO-J 300 MHz) δ 10.33 (s, IH), 7.65 (m, 2H), 7.38 (d, 2H), 7.03
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.35 (broad t, 2H), 4.63 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.44-1.79 (m, 6H), 1.03 (t, 3H).
[271]
[272] Example 38: 13-(4-Trifluoromethylbenzyl)-9-0-(4-te/t - butylbenzyl)berberrubine bromide (Compound No. 38)
[273] 0.09 g of 13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide was obtained in the same manner as in the aforementioned Example 36, except that 4-tert-butylbenzyl bromide was used instead of butyl iodide.
[274] λ H-NMR (DMSO-J 300 MHz) δ 10.33 (s, IH), 7.76 (d, 2H), 7.64 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.64 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 1.34 (s, 9H).
[275]
[276] Example 39: 13-(4-i'e/t-Butylbenzyl)-9-0-propylberberrubine chloride
(Compound No. 39)
[277] 0.2 g of 13-(4-tert-butylbenzyl)-9-0-propylberberrubine iodide obtained in the aforementioned Example 7 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring the mixture at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-tert-butylbenzyl)-9-0-propylberberrubine chloride.
[278] λ H-NMR (DMSO-J 300 MHz) δ 10.27 (s, IH), 7.63 (m, 2H), 7.32 (d, 2H), 7.02
(s, IH), 6.96 (s, 2H), 6.84 (s, IH), 5.96 (s, 2H), 5.36 (broad t, 2H), 4.63 (s, 2H), 4.54 (t, 2H) 4.02 (s, 3H) 3.31 (t, 2H) 2.04 (m, 2H), 1.35 (s, 9H), 1.04 (t, 3H).
[279]
[280] Example 40: 13-(4-te/t-Butylbenzyl)-9-O-butylberberrubine chloride
(Compound No. 40)
[281 ] 0.2 g of 13-(4-tert-butylbenzyl)-9-O-butylberberrubine iodide obtained in the aforementioned Example 8 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of l3-(4-tert- butylbenzyl)-9- 0-butylberberrubine chloride.
[282] λ H-NMR (DMSO-J 300 MHz) δ 10.27 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.87 (s, IH), 5.99 (s, 2H), 5.38 (broad t, 2H), 4.62 (s, 2H), 4.57 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.32 (s, 9H), 1.03 (t, 3H).
[283]
[284] Example 41: 13-(4-i'e/t-Butylbenzyl)-9-O-hexylberberrubine chloride
(Compound No. 41)
[285] 0.2 g of 13-(4-tert-butylbenzyl)-9-0-hexylberberrubine iodide obtained in the aforementioned Example 9 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-terf-butylb enzyl)-9-O-hexylberberrubine chloride.
[286] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.67 (m, 2H), 7.38 (d, 2H), 7.04
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.43-1.79 (m, 6H), 1.31 (s, 9H), 1.05 (t, 3H).
[287]
[288] Example 42: 13-(4-te/*-Butylbenzyl)-9-0-octylberberrubine chloride
(Compound No. 42)
[289] 0.2 g of 13-(4-terf-butylbenzyl)-9-O-octylberberrubine iodide obtained in the aforementioned Example 10 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of l3-(4-tert-
butylbenzyl)-9- 0-octylberberrubine chloride.
[290] λ H-NMR (DMSO-J 300 MHz) δ 10.28 (s, IH), 7.69 (m, 2H), 7.40 (d, 2H), 7.07
(s, IH), 6.95 (s, 2H), 6.88 (s, IH), 5.98 (s, 2H), 5.35 (broad t, 2H), 4.64 (s, 2H), 4.54 (t, 2H) 4.04 (s, 3H) 3.25 (t, 2H) 2.06 (m, 2H), 1.44-1.80 (m, 10H), 1.33 (s, 9H), 1.03 (t, 3H).
[291]
[292] Example 43: 13-(4-te/*-Butylbenzyl)-9-0-(34iydroxypropyl)berberrubine chloride (Compound No. 43)
[293] 0.2 g of 13-(4-tert-butylbenzyl)-9-O-(3-hydroxypropyl)berberrubine iodide obtained in the aforementioned Example 11 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-tert-butylbenzyl)-9-O-(3-hydroxypropyl)berberrubine chloride.
[294] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.56 (s, IH), 7.65 (m, 2H), 7.37 (d, 2H), 7.03
(s, IH), 7.00 (s, 2H), 6.87 (s, IH), 6.00 (s, 2H), 5.20 (broad t, 2H), 4.69 (t, 2H), 4.63 (s, 2H), 4.05(t, 2H), 4.02 (s, 3H) 3.28 (t, 2H) 2.25 (m, 2H), 1.32 (s, 9H).
[295]
[296] Example 44: 13-(4-i'e/t-Butylbenzyl)-9-0-(6-chlorohexyl)berberrubine chloride (Compound No. 44)
[297] 0.2 g of 13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberrubine iodide obtained in the aforementioned Example 12 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberrubine chloride.
[298] λ H-NMR (DMSO-J 300 MHz) δ 10.30 (s, IH), 7.66 (m, 2H), 7.35 (d, 2H), 7.02
(d, 2H), 7.00 (s, IH), 6.87 (s, IH), 6.00 (s, 2H), 5.21 (broad t, 2H), 4.63 (s, 2H), 4.61 (t, 2H), 4.01 (s, 3H), 3.60 (t 2H), 3.30 (t, 2H) 2.10 (m, 2H), 1.89 (m, 2H), 1.58-1.64 (m, 4H), 1.32 (s, 9H).
[299]
[300] Example 45: 13-(4-te/*-Butylbenzyl)-9-0-allylberberrubine chloride
(Compound No. 45)
[301] 0.2 g of 13-(4-tert-butylbenzyl)-9-O-allylberberrubine iodide obtained in the aforementioned Example 13 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-tert-butylbenzyl)-9 - O-allylberberrubine chloride.
[302] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.55 (s, IH), 7.65 (m, 2H), 7.36 (d, 2H), 7.03
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.49(m, IH), 6.00 (s, 2H), 5.5 (dd, IH), 5.33 (dd,
IH), 5.13 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.29 (t, 2H), 1.32 (s, 9H). [303] [304] Example 46: 13-(4-i'e/t-Butylbenzyl)-9-0-crotylberberrubine chloride
(Compound No. 46)
[305] 0.2 g of 13-(4-tert-butylbenzyl)-9-O-crotylberberrubine iodide obtained in the aforementioned Example 14 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of l3-(4-tert- butylbenzyl)-9- 0-crotylberbeπubine chloride.
[306] λ H-NMR (DMSO-J 300 MHz) δ 10.52 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.12(m, 2H), 6.00 (s, 2H), 5.31 (broad, 2H), 5.06 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.30 (t, 2H), 1.77 (d, 3H), 1.32 (s, 9H).
[307]
[308] Example 47: 13-(4-te/t-Butylbenzyl)-9-O-(4-te/t-butylbenzyl)berberrubine chloride (Compound No. 47)
[309] 0.2 g of 13-(4-tert-butylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine iodide obtained in the aforementioned Example 15 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-tert-butylbenzyl)-9-O-(4-terf-butylbenzyl)berberrubine chloride.
[310] λ H-NMR (DMSO-J 300 MHz) δ 10.34 (s, IH), 7.77 (d, 2H), 7.66 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 1.34 (s, 9H), 1.32 (s, 9H).
[311]
[312] Example 48: 13-(4-l'e/t-Butylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine chloride (Compound No. 48)
[313] 0.2 g of l 3-(4-terf-butylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine iodide obtained in the aforementioned Example 16 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-tert-butylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine chloride.
[314] λ H-NMR (DMSO-J 300 MHz) δ 10.38 (s, IH), 7.77 (d, 2H), 7.67 (m, 2H), 7.36
(d, 2H), 7.28(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.99 (s, 2H), 5.63 (s, 2H), 5.20 (broad t, 2H), 4.62 (s, 2H), 4.04 (s, 3H), 3.30 (t, 2H), 2.91 (m, IH), 1.32 (s, 9H), 1.24 (d, 6H).
[315]
[316] Example 49: 13-(4-Isopropylbenzyl)-9-0-propylberberrubine chloride
(Compound No. 49)
[317] 0.2 g of 13-(4-isopropylbenzyl)-9-0-propylberberrubine iodide obtained in the aforementioned Example 17 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-0-propylberberrubine chloride.
[318] λ H-NMR (DMSO-J 300 MHz) δ 10.26 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.01
(s, IH), 6.96 (s, 2H), 6.83 (s, IH), 5.96 (s, 2H), 5.32 (broad t, 2H), 4.64 (s, 2H), 4.53 (t, 2H), 4.02 (s, 3H), 3.32 (t, 2H), 2.91 (m, IH), 2.04 (m, 2H), 1.25 (d, 6H), 1.04 (t, 3H).
[319]
[320] Example 50: 13-(4-Isopropylbenzyl)-9-0-butylberberrubine chloride
(Compound No. 50)
[321] 0.2 g of 13-(4-isopropylbenzyl)-9-0-butylberberrubine iodide obtained in the aforementioned Example 18 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-O-butylberberrubine chloride.
[322] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.63 (m, 2H), 7.36 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.87 (s, IH), 5.99 (s, 2H), 5.38 (broad t, 2H), 4.64 (s, 2H), 4.52 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.91 (m, IH), 2.07 (m, 2H), 1.63 (m, 2H), 1.26 (d, 6H), 1.04 (t, 3H).
[323]
[324] Example 51: 13-(4-Isopropylbenzyl)-9-0-hexylberberrubine chloride
(Compound No. 51)
[325] 0.2 g of 13-(4-isopropylbenzyl)-9-O-hexylberberrubine iodide obtained in the aforementioned Example 19 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-O-hexylberberrubine chloride.
[326] λ H-NMR (DMSO-J 300 MHz) δ 10.32 (s, IH), 7.67 (m, 2H), 7.36 (d, 2H), 7.04
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.91 (m, IH), 2.04 (m, 2H), 1.43-1.78 (m, 6H), 1.25 (d, 6H), 1.05 (t, 3H).
[327]
[328] Example 52: 13-(4-Isopropylbenzyl)-9-0-octylberberrubine chloride
(Compound No. 52)
[329] 0.2 g of 13-(4-isopropylbenzyl)-9-O-octylberberrubine iodide obtained in the aforementioned Example 20 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was
filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-0-octylberberrubine chloride.
[330] λ H-NMR (DMSO-J 300 MHz) δ 10.28 (s, IH), 7.69 (m, 2H), 7.40 (d, 2H), 7.07
(s, IH), 6.95 (s, 2H), 6.88 (s, IH), 5.98 (s, 2H), 5.35 (broad t, 2H), 4.64 (s, 2H), 4.54 (t, 2H) 4.04 (s, 3H) 3.25 (t, 2H) 2.92 (m, IH), 2.06 (m, 2H), 1.44-1.81 (m, 10H), 1.27 (d, 6H), 1.03 (t, 3H).
[331]
[332] Example 53: 13-(4-Isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine chloride (Compound No. 53)
[333] 0.2 g of 13-(4-isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide obtained in the aforementioned Example 21 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-O-(3-hydroxypropyl)berberrubine chloride.
[334] λ H-NMR (DMSO-J 300 MHz) δ 10.26 (s, IH), 7.65 (m, 2H), 7.37 (d, 2H), 7.03
(s, IH), 7.00 (s, 2H), 6.87 (s, IH), 6.00 (s, 2H), 5.20 (broad t, 2H), 4.69 (t, 2H), 4.63 (s, 2H), 4.05(t, 2H), 4.02 (s, 3H), 3.28 (t, 2H), 2.90 (m, IH), 2.25 (m, 2H), 1.27 (d, 6H).
[335]
[336] Example 54: 13-(4-Isopropylbenzyl)-9-0-(6-chlorohexyl)berberrubine chloride (Compound No. 54)
[337] 0.2 g of 13-(4-isopropylbenzyl)-9-O-(6-chlorohexyl)berberrubine iodide obtained in the aforementioned Example 22 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-O-(6-chlorohexyl)berberrubine chloride.
[338] λ H-NMR (DMSO-J 300 MHz) δ 10.30 (s, IH), 7.66 (m, 2H), 7.35 (d, 2H), 7.02
(d, 2H), 7.00 (s, IH), 6.87 (s, IH), 6.00 (s, 2H), 5.21 (broad t, 2H), 4.63 (s, 2H), 4.61 (t, 2H), 4.01 (s, 3H), 3.60 (t 2H), 3.30 (t, 2H), 2.91 (m, IH), 2.10 (m, 2H), 1.89 (m, 2H), 1.58-1.64 (m, 4H), 1.28 (d, 6H).
[339]
[340] Example 55: 13-(4-Isopropylbenzyl)-9-0-allylberberrubine chloride
(Compound No. 55)
[341] 0.2 g of 13-(4-isopropylbenzyl)-9-O-allylberberrubine iodide obtained in the aforementioned Example 23 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9 - 0-allylberberrubine chloride.
[342] λ H-NMR (DMSO-J 6 , 300 MHz) δ 10.25 (s, IH), 7.65 (m, 2H), 7.36 (d, 2H), 7.03
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.49(m, IH), 6.00 (s, 2H), 5.5 (dd, IH), 5.33 (dd, IH), 5.13 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.29 (t, 2H), 2.92 (m, IH), 1.26 (d, 6H).
[343]
[344] Example 56: 13-(4-isopropylbenzyl)-9-0-crotylberberrubine chloride
(Compound No. 56)
[345] 0.2 g of 13-(4-isopropylbenzyl)-9-0-crotylberberrubine iodide obtained in the aforementioned Example 24 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-0-crotylberberrubine chloride.
[346] λ H-NMR (DMSO-J 300 MHz) δ 10.30 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H), 7.02
(d, 2H), 6.99 (s, IH), 6.87 (s, IH), 6.12(m, 2H), 6.00 (s, 2H), 5.31 (broad, 2H), 5.06 (d, 2H), 4.62 (s, 2H), 4.01 (s, 3H) 3.30 (t, 2H), 2.91 (m, IH), 1.77 (d, 3H), 1.26 (d, 6H).
[347]
[348] Example 57: 13-(4-Isopropylbenzyl)-9-0-(4-te/t-butylbenzyl)berberrubine chloride (Compound No. 57)
[349] 0.2 g of 13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine iodide obtained in the aforementioned Example 25 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride.
[350] λ H-NMR (DMSO-J 300 MHz) δ 10.34 (s, IH), 7.77 (d, 2H), 7.66 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 2.91 (m, IH), 1.32 (s, 9H), 1.26 (d, 6H).
[351]
[352] Example 58: 13-(4-Isopropylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine chloride (Compound No. 58)
[353] 0.2 g of 13-(4-isopropylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine iodide obtained in the aforementioned Example 26 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-isopropylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine chloride.
[354] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.78 (d, 2H), 7.67 (m, 2H), 7.36
(d, 2H), 7.28(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.85 (s, IH), 5.99 (s, 2H), 5.63 (s, 2H), 5.20 (broad t, 2H), 4.62 (s, 2H), 4.04 (s, 3H), 3.30 (t, 2H) 2.91 (m, 2H), 1.27 (d, 6H), 1.24 (d, 6H).
[355]
[356] Example 59: 13-(3,4,5-trifluorobenzyl)-9-0-butylberberrubine chloride
(Compound No. 59)
[357] 0.2 g of 13-(3,4,5-trifluorobenzyl)-9-O-butylberberrubine iodide obtained in the aforementioned Example 27 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(3,4,5-trifluorobenzyl)-9-0-butylberberrubine chloride.
[358] λ H-NMR (DMSO-J 300 MHz) δ 10.26 (s, IH), 7.64 (s, IH), 7.36 (s, IH), 7.01
(s, IH), 6.96 (s, 2H), 6.83 (s, IH), 5.96 (s, 2H), 5.34 (broad t, 2H), 4.63 (s, 2H), 4.52 (t, 2H), 4.01 (s, 3H), 3.33 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.04 (t, 3H).
[359]
[360] Example 60: 13-(3,4,5-Trifluorobenzyl)-9-0-hexylberberrubine chloride
(Compound No. 60)
[361] 0.2 g of 13-(3,4,5-trifluorobenzyl)-9-0-hexylberberrubine iodide obtained in the aforementioned Example 28 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(3,4,5-trifluorobenzyl)-9-O-hexylberberrubine chloride.
[362] λ H-NMR (DMSO-J 300 MHz) δ 10.32 (s, IH), 7.62 (s, IH), 7.34 (s, IH), 7.01
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.43-1.78 (m, 6H), 1.05 (t, 3H).
[363]
[364] Example 61: 13-(3,4,5-Trifluorobenzyl)-9-0-(4-l'e/t-butylbenzyl)berberrubine chloride (Compound No. 61)
[365] 0.2 g of 13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine iodide obtained in the aforementioned Example 29 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride.
[366] λ H-NMR (DMSO-J 300 MHz) δ 10.32 (s, IH), 7.77 (d, 2H), 7.62 (m, 2H), 7.34
(s, IH), 7.01 (s, 2H), 6.93 (s, 2H), 6.86 (s, IH), 5.98 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.63 (s, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 1.32 (s, 9H).
[367]
[368] Example 62: 13-(3,4,5-Trimethoxybenzyl)-9-0-butylberberrubine chloride
(Compound No. 62)
[369] 0.2 g of 13-(3,4,5-trimethoxybenzyl)-9-O-butylberberrubine iodide obtained in the aforementioned Example 30 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was
filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(3,4,5- trimethoxybenzyl)-9-0-butylberberrubine chloride.
[370] λ H-NMR (DMSO-J 300 MHz) δ 10.28 (s, IH), 7.65 (s, IH), 7.36 (s, IH), 7.03
(s, IH), 6.96 (s, 2H), 6.83 (s, IH), 5.96 (s, 2H), 5.28 (broad t, 2H), 4.62 (s, 2H), 4.52 (t, 2H), 4.05 (s, 6H), 4.03 (s, 3H), 3.33 (t, 2H), 2.07 (m, 2H), 1.64 (m, 2H), 1.03 (t, 3H).
[371]
[372] Example 63: 13-(3,4,5-Trimethoxybenzyl)-9-0-hexylberberrubine chloride
(Compound No. 63)
[373] 0.2 g of 13-(3,4,5-trimethoxybenzyl)-9-0-hexylberberrubine iodide obtained in the aforementioned Example 31 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(3,4,5-trimethoxybenzyl)-9-O-hexylberberrubine chloride.
[374] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.31 (s, IH), 7.64 (s, IH), 7.33 (s, IH), 7.03
(s, IH), 6.92 (s, 2H), 6.85 (s, IH), 5.97 (s, 2H), 5.32 (broad t, 2H), 4.63 (s, 2H), 4.56 (t, 2H), 4.04 (s, 6H), 4.02 (s, 3H), 3.24 (t, 2H), 2.05 (m, 2H), 1.41-1.79 (m, 6H), 1.05 (t, 3H).
[375]
[376] Example 64: 13-(3,4,5-Trimethoxybenzyl)-9-0-(4-te/t- butylbenzyl)berberrubine chloride (Compound No. 64)
[377] 0.2 g of 13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine iodide obtained in the aforementioned Example 32 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride.
[378] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.76 (d, 2H), 7.63 (m, 2H), 7.34
(s, IH), 7.01 (s, 2H), 6.93 (s, 2H), 6.86 (s, IH), 5.98 (s, 2H), 5.61 (s, 2H), 5.22 (broad t, 2H), 4.65 (s, 2H), 4.04(s, 6H), 4.02 (s, 3H), 3.24 (t, 2H), 1.33 (s, 9H).
[379]
[380] Example 65: 13-(4-Trifluoromethoxybenzyl)-9-0-butylberberrubine chloride
(Compound No. 65)
[381] 0.2 g of 13-(4-trifluoromethoxybenzyl)-9-O-butylberberrubine iodide obtained in the aforementioned Example 33 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-trifluoromethoxybenzyl)-9-O-butylberberrubine chloride.
[382] λ H-NMR (DMSO-J ^ 300 MHz) δ : 10.27 (s, IH), 7.64 (m, 2H), 7.36 (d, 2H),
7.02 (s, IH), 6.98 (s, 2H), 6.87 (s, IH), 5.99 (s, 2H), 5.38 (broad t, 2H), 4.62 (s, 2H),
4.57 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.03 (t, 3H). [383] [384] Example 66: 13-(4-Trifluoromethoxybenzyl)-9-0-hexylberberrubine chloride
(Compound No. 66)
[385] 0.2 g of 13-(4-trifluoromethoxybenzyl)-9-O-hexylberberrubine iodide obtained in the aforementioned Example 34 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-trifluoromethoxybenzyl)-9-0-hexylberberrubine chloride.
[386] λ H-NMR (DMSO-J 300 MHz) δ 10.31 (s, IH), 7.67 (m, 2H), 7.38 (d, 2H), 7.04
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.34 (broad t, 2H), 4.65 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.43-1.79 (m, 6H), 1.05 (t, 3H).
[387]
[388] Example 67: 13-(4-Trifluoromethoxybenzyl)-9-0-(4-te/f- butylbenzyl)berberrubine chloride (Compound No. 67)
[389] 0.2 g of 13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine iodide obtained in the aforementioned Example 35 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride.
[390] λ H-NMR (DMSO-J 300 MHz) δ 10.34 (s, IH), 7.77 (d, 2H), 7.66 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.62 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 1.32 (s, 9H).
[391]
[392] Example 68: 13-(4-Trifluoromethylbenzyl)-9-0-butylberberrubine chloride
(Compound No. 68)
[393] 0.2 g of 13-(4-trifluoromethylbenzyl)-9-O-butylberberrubine iodide obtained in the aforementioned Example 36 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-trifluoromethylbenzyl)-9-O-butylberberrubine chloride.
[394] λ H-NMR (DMSO-J 300 MHz) δ 10.25 (s, IH), 7.64 (m, 2H), 7.35 (d, 2H), 7.02
(s, IH), 6.98 (s, 2H), 6.85 (s, IH), 5.99 (s, 2H), 5.35 (broad t, 2H), 4.62 (s, 2H), 4.57 (t, 2H), 4.00 (s, 3H), 3.27 (t, 2H), 2.07 (m, 2H), 1.63 (m, 2H), 1.03 (t, 3H).
[395]
[396] Example 69: 13-(4-Trifluoromethylbenzyl)-9-0-hexylberberrubine chloride
(Compound No. 69)
[397] 0.2 g of 13-(4-trifluoromethylbenzyl)-9-O-hexylberberrubine iodide obtained in the
aforementioned Example 37 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-trifluoromethylbenzyl)-9-0-hexylberberrubine chloride.
[398] λ H-NMR (DMSO-J 300 MHz) δ 10.33 (s, IH), 7.65 (m, 2H), 7.38 (d, 2H), 7.03
(s, IH), 6.93 (s, 2H), 6.86 (s, IH), 5.97 (s, 2H), 5.35 (broad t, 2H), 4.63 (s, 2H), 4.56 (t, 2H), 4.02 (s, 3H), 3.24 (t, 2H), 2.04 (m, 2H), 1.44-1.79 (m, 6H), 1.03 (t, 3H).
[399]
[400] Example 70: 13-(4-Trifluoromethylbenzyl)-9-0-(4-te/*-butylbenzy l)berberrubine chloride (Compound No. 70)
[401] 0.2 g of 13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine iodide obtained in the aforementioned Example 38 was dissolved in methanol (MeOH) and 0.1 g of silver chloride (AgCl) was added. After stirring at 60 °C for 1 hour, the reaction solution was filtered and concentrated under reduced pressure to obtain 0.18 g of 13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride.
[402] λ H-NMR (DMSO-J ^ 300 MHz) δ 10.33 (s, IH), 7.76 (d, 2H), 7.64 (m, 2H), 7.36
(d, 2H), 7.27(s, 2H), 7.02 (d, 2H), 6.98 (s, IH), 6.86 (s, IH), 5.97 (s, 2H), 5.64 (s, 2H), 5.22 (broad t, 2H), 4.62 (s, 2H), 4.03 (s, 3H), 3.31 (t, 2H), 1.34 (s, 9H).
[403] The novel compound of the present invention represented by the formula (1) can be prepared into various preparation forms depending on the purposes specified. Some non-restrictive preparation examples of the compound of the present invention represented by the aforementioned formula (1) are given below.
[404]
[405] Preparation Examples
[406] Preparation Example 1: Tablets (direct pressing)
[407] 5.0 mg of the active ingredient was sieved and mixed with 14.1 mg of lactose, 0.8 mg of Crospovidone USNF and 0.1 mg of magnesium stearate. The mixture was pressed to form a tablet.
[408]
[409] Preparation Example 2: Tablets (wet granulation)
[410] 5.0 mg of the active ingredient was sieved and mixed with 16.0 mg of lactose and
4.0 mg of starch. A solution obtained by dissolving 80 0.3 mg of polysorbate in pure water was added and the resultant mixture was granulated. After drying, the resultant granule was sieved and mixed with 2.7 mg of colloidal silicon dioxide and 2.0 mg of magnesium stearate. The granule was pressed to form a tablet.
[411]
[412] Preparation Example 3: Powder and capsule
[413] 5.0 mg of the active ingredient was sieved and mixed with 14.8 mg of lactose, 10.0
mg of polyvinylpyrrolidone and 0.2 mg of magnesium stearate. The mixture was filled into a No. 5 gelatin capsule using a suitable apparatus.
[414]
[415] Preparation Example 4: Injection form
[416] An injection form was prepared by mixing 100 mg of the active ingredient, 180 mg of mannitol, 26 mg of Na HPO • 12H O and 2974 mg of distilled water.
[417] The inhibitory activity against chitin synthase and antifungal activity against human pathogenic fungi of the novel compound in accordance with the present invention were tested as follows.
[418]
[419] Test Examples
[420] Test Example 1: Preparation of chitin synthase 1 crude enzyme of Candida albicans
[421] Crude enzyme was prepared using the Candida albicans chsl A chs 3 Δ mutant ( chs2 Δ ::hisGlchs2 Δ v.hisG chs3 Δ ::hisG/chs3 Δ v.hisG) strain, which can only produce the chitin synthase 1. The strain was inoculated with the SDA (Sabouraud dextrose agar) culture medium (4 % dextrose, 1 % peptone, pH 5.6) and cultured at 30 °C for 15-17 hours until the absorbance at 550nm reaches 0.7. The cells were collected and suspended in a 50 mM Tris-HCl (pH 7.5) buffer solution containing 5 mM magnesium acetate. After centrifugation at 8,000 x g for 10 minutes, the pellets were suspended in the same Tris-HCl buffer solution. The suspension was divided into aliquots in 50 mL conical test tubes. After adding glass beads, the cells were disrupted by vigorously vortexing with an interval of 30 seconds. The cell residues were removed by centrifuging at 3,000 x g for 5 minutes. The supernatant was ultra- centrifuged at 130,000 x g for 1 hour. The resultant pellets were collected and suspended in 50 mM Tris-HCl (pH 7.5) containing 33 % glycerol, to a final volume of 1.6 mg/g (wet weight) of yeast used. The suspension was divided into aliquots and kept at -70 °C until it is used.
[422]
[423] Test Example 2: Preparation of chitin synthase 2 crude enzyme of Sac- charomyces cerevisiae
[424] Crude enzyme was prepared using the recombinant Sαcchαromyces cerevisiae
ECY38-38A(pAS6) (MATa chsl-23 chs2::LEU2 cal llcsdl ura 3-52 trp 1-1 leu 2-2 pAS6) strain, which can produce the chitin synthase 2 only. The strain was inoculated with the YPG culture medium (1 % yeast extract, 2 % peptone, 2 % galactose) and cultured at 30 °C overnight. Then, it was inoculated with a fresh YPG culture medium and cultured for 15-17 hours until the Absorbance at 550nm reaches 1.0. The cells were collected and suspended in 50 mM Tris-HCl (pH 7.5) buffer containing 5 mM
magnesium acetate. After centrifugation at 8,000xg for 10 minutes, the pellets were suspended in the same Tris-HCl buffer solution. The suspension was divided into aliquots in 50 mL conical test tubes. After adding the glass beads, the cells were disrupted by vigorously vortexing with an interval of 30 seconds. The cell residues were removed by centrifuging at 3,000xg for 5 minutes. The supernatant was ultra- centrifuged at 130,000xg for 1 hour. The resultant pellets were collected and suspended in 50 mM Tris-HCl (pH 7.5) containing 33 % glycerol, to a final volume of 1.6 mg/g (wet weight) of yeast used. The suspension was divided into aliquots and kept at -70 °C until it is used.
[425]
[426] Test Example 3: In vitro enzyme assays for chitin synthase 1 of Candida albicans and chitin synthase 2 of Saccharomyces cerevisiae
\42T\ The inhibitory activities against the chitin synthase 1 of Candida albicans chs2 Δ chs 3 Δ (abbreviated as 'enzyme 1') and the chitin synthase 2 of Saccharomyces cerevisiae ECY38-38A(pAS6)(abbreviated as 'enzyme 2') was examined for compound Nos. 1 to 70 compound and polyoxin D, a positive control compound. The result is given in Tables 1 to 3 below.
[428] The inhibitory activity against the chitin synthase 1 prepared from Candida albicans and the chitin synthase 2 prepared from Saccharomyces cerevisiae were examined as follows. A reaction mixture containing 32 mM Tris-HCl (pH 7.5), 2 mM cobalt acetate, 1.1 mM UDP-[U-14C]-N-acetyl-d-glucosamine (GIcNAc) (400,000 cpm/μmol), 2 μL of trypsin (0.75 mg/mL), 20 μL of each crude enzyme and 14 μL of each test sample was kept at 30 °C for 15 minutes to activate the enzyme. Then, 2 μL of trypsin inhibitor (1.5 mg/mL) was added and the mixture was kept in an ice bath for 10 minutes to deactivate trypsin. 2 μL of 0.8 M N-acetyl-d-glucosamine was added to a total volume of 50 μL and reaction was performed at 30 °C for 90 minutes. The reaction was stopped using 1 mL of 10 % TCA solution and the reaction solution was filtered with a GF/C filter and dried at room temperature. After adding 3 mL of a scintillation cocktail solution, the amount of isotopes was measured using a liquid scintillation counter. Percentage inhibition against each enzyme was calculated by the following Equation 1.
Sample(cpm) - Untreated(cpm)
Inhibition (%) = 1 - x 100
Control(cpm) - Untreated(cpm)
[429] The control group was not added with a test sample in the reaction mixture and that of the untreated group contained neither the test sample nor the crude enzyme .
[430] The relative activities given in Tables 1 to 3 show the relative values of inhibitory activity of polyoxin D, which is known to have superior inhibitory activity against the
aforementioned two enzymes. A 50 % inhibitory activity of polyoxin D against the enzyme was given the value 5. A compound having the same inhibitory activity as that of polyoxin D at the same concentration was given the value 5. Compounds having the inhibitory activity at 2-fold, 4-fold, 8-fold and 16-fold higher concentrations than that of polyoxin D were given the values of 4, 3, 2 and 1, respectively. On the other hand, compounds having the inhibitory activity at 1/2, 1/4 and 1/8 lower concentrations than that of polyoxin D were given the values of 6, 7 and 8, respectively. Table 1
[436] [437] Test Example 4: Antifungal activity against human pathogenic fungi [438] In vitro antifungal activity (MIC) against human pathogenic fungi was examined for the compounds that showed potent inhibitory activities against the chitin synthases and amphotericin B, a control compound. The result is given in Table 4 below.
[439] Candida albicans ATCC 10231, Candida lusitaniae ATCC 42720, Candida krusei ATCC 6258, Candida tropicalis ATCC 13803, Candida glabrata ATCC 48435, Candida parapsilosis ATCC 34136, Cryptococcus neoformans ATCC 36556, As-
pergillus fumigatus ATCC 16424, Aspergillus flavus ATCC 64025, Aspergillus terreus ATCC 46941 and Mucor ramosissimus ATCC 90286 strains for the MIC (minimum inhibitory concentration) measurement were obtained from ATCC (American Type Culture Collection) in the U.S. The Candida albicans A207(clinical isolate) strain was used by isolating it from the patients. The determination of MIC was performed according to the NCCLS (National
Committee for Clinical Laboratory Standard) method. Each test sample solution was diluted two-fold and inoculated with a fungal suspension to reach a final inoculum size of 5 x 10 to 2.5 xlO cell/mL . The Cryptococcus neoformans strain was cultured in the RPMI 1640 medium for 72 hours. Other strains were cultured for 48 hours. MIC was determined as the lowest concentration of the compound that completely inhibited the growth of the fungi by comparing with a control not containing the compound.
Table 4
[446] The novel compounds in accordance with the present invention were confirmed to have superior antifungal activity. In particular, when compared with the compound having the best activity of those disclosed in Korean Patent No. 258,849 (Comparative Compound No. 1; tert-butyl benzyl group is introduced at the C- 13 position of
berberine having methoxy groups at the C-9 and C-IO positions), the compounds of the present invention in which a methoxy group is introduced at the C-10 position and a relatively long C -C alkoxy chain is introduced at the C-9 position showed 10-fold or more of antifungal activities against most of the 12 human pathogenic fungi. In some strains, the antifungal activity was 32 to 64-fold more potent. In particular, whereas the compound disclosed in Korean Patent No. 258,849 (Comparative Compound No. 1) showed no antifungal activities against the Candida glabrata and Candida parapsilosis strains at all, the compound of the present invention showed 128-fold or more of antifungal activities. Furthermore, the antifungal activity against the Aspergillus strain, which has drawn a lot of concerns recently, was 32 to 64- fold or better.
[447] [448] Test Example 5: Acute oral toxicity [449] Toxicity of compound No. 8, which shows a potent inhibitory effect against the chitin synthases and fungi and has the solubility adequate for the toxicity test, and compound No. 50, which has been transferred from iodide to chloride to improve the solubility, was examined on mice. Each compound was suspended in 1 % car- boxymethylcellulose (CMC), and orally and abdominally administered to 6-week-old male ICR mice. General symptoms, weight change and deaths were observed for a week under normal breeding condition. Then, an autopsy was performed on the mice. The results are given in Table 5 below. Table 5
[450] Of the compounds in accordance with the present invention, the iodides compound Nos. 7, 8, 17 and 18 and the chlorides compound Nos. 39, 40, 49 and 50 showed superior inhibitory activities against the chitin synthases, which are essential in the growth of fungi. And, the MICs of the iodides compound Nos. 7, 8, 17 and 18 and the chlorides compound Nos. 39, 40, 49 and 50 showed 500-1,000 times or more of antifungal activities than that of the berberrubine, the starting material (MIC = 256-512 μg/mL).
[451]
Industrial Applicability
[452]
[453] Since fungi are eukaryotic organisms, most of conventional antifungal agents are toxic to human. However, because chitin synthase is an essential enzyme present only in fungi, a selective antifungal activity may be attained without human toxicity if the activity of the enzyme can be inhibited effectively. Most of the compounds of the present invention showed superior inhibitory activities against chitin synthase. Among them, compounds Nos. 7, 8, 17, 18, 39, 40, 49 and 50 showed exceptionally superior inhibitory activities. Also, they showed antifungal activities comparable to that of amphotericin B, which is an antifungal agent used to treat systemic fungal infection. In toxicity test with mice, compound No. 8 showed no abnormalities in general symptoms and body weight with the oral administration dosage of 1,000 mg/kg. And there was no case of death observed. Accordingly, the compounds in accordance with the present invention have superior inhibitory activities against chitin synthase, antifungal activities comparable to that of amphotericin B, with less toxicity.
[454] Those skilled in the art will appreciate that the concepts and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the present invention as set forth in the appended claims.
Claims
[1] A berberrubine derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof:
wherein R is benzyl or substituted benzyl; R is ketone (=O) or OR, wherein R is C -C alkyl, C -C haloalkyl, C -C hydroxyalkyl, C -C alkenyl, benzyl or substituted benzyl; and the substituted benzyl has 1 to 4 substituents selected from halogen atom, C -C alkyl, C -C haloalkyl, C -C alkoxy and C -C
° 1 6 "7 I O J \ 6 1 6 haloalkoxy.
[3] The compound as set forth in Claim 1, wherein the pharmaceutically acceptable salt is a halide or an acid adduct of an inorganic acid or organic acid.
[4] The compound as set forth in Claim 1, which is selected from
13-(3,4,5-trifluorobenzyl)berberrubine (Compound No. 1), 13-(3,4,5-trimethoxybenzyl)berberrubine (Compound No. 2), 13-(4-trifluoromethoxybenzyl)berberrubine (Compound No. 3), 13-(4-trifluoromethylbenzyl)berberrubine (Compound No. 4), 13-(4-tert-butylbenzyl)berberrubine (Compound No.
5), 13-(4-isopropylbenzyl)berberrubine (Compound No.
6), 13-(4-tert-butylbenzyl)-9-0-propylberberrubine iodide (Compound No.
7), 13-(4-tert-butylbenzyl)-9-0-butylberberrubine iodide (Compound No.
8), 13-(4-tert-butylbenzyl)-9-0-hexylberberrubine iodide (Compound No.
9), 13-(4-tert-butylbenzyl)-9-O-octylberberrubine iodide (Compound No.
10), 13-(4-tert-butylbenzyl)-9-O-(3-hydroxypropyl)berberrubine iodide (Compound No.
11),
13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberrubine iodide (Compound No.
12),
13-(4-tert-butylbenzyl)-9-0-allylberberrubine iodide (Compound No. 13), 13-(4-tert-butylbenzyl)-9-O-crotylberberrubine bromide (Compound No.
14),
13-(4-tert-butylbenzyl)-9-O-(4-tert-butylbenzyl)berberτubine bromide
(Compound No. 15),
13-(4-tert-butylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine bromide
(Compound No. 16),
13-(4-isopropylbenzyl)-9-0-propylberberrubine iodide (Compound No.
17),
13-(4-isopropylbenzyl)-9-0-butylberberrubine iodide (Compound No.
18),
13-(4-isopropylbenzyl)-9-0-hexylberberrubine iodide (Compound No.
19),
13-(4-isopropylbenzyl)-9-0-octylberberrubine iodide (Compound No.
20),
13-(4-isopropylbenzyl)-9-0-(3-hydroxypropyl)berberrubine iodide (Compound
No.
21),
13-(4-isopropylbenzyl)-9-0-(6-chlorohexyl)berbeπubine iodide (Compound No.
22),
13-(4-isopropylbenzyl)-9-0-allylberberrubine iodide (Compound No.
23),
13-(4-isopropylbenzyl)-9-0-crotylberberrubine bromide (Compound No.
24),
13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berbeπubine bromide
(Compound No. 25),
13-(4-isopropylbenzyl)-9-0-(4-isopropylbenzyl)berberrubine bromide
(Compound No. 26),
13-(3,4,5-trifluorobenzyl)-9-0-butylberberrubine iodide (Compound No.
27),
13-(3,4,5-trifluorobenzyl)-9-0-hexylberberrubine iodide (Compound No.
28),
13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 29),
13-(3,4,5-trimethoxybenzyl)-9-0-butylberberrubine iodide (Compound No.
30),
13-(3,4,5-trimethoxybenzyl)-9-0-hexylberberrubine iodide (Compound No.
31),
13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(32),
13-(4-trifluoromethoxybenzyl)-9-0-butylberberrubine iodide (Compound No.
33),
13-(4-trifluoromethoxybenzyl)-9-0-hexylberberrubine iodide (Compound No.
34),
13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 35),
13-(4-trifluoromethylbenzyl)-9-O-butylberberrubine iodide (Compound No.
36),
13-(4-trifluoromethylbenzyl)-9-O-hexylberberrubine iodide (Compound No.
37),
13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine bromide
(Compound No. 38),
13-(4-tert-butylbenzyl)-9-O-propylberberrubine chloride (Compound No.
39),
13-(4-tert-butylbenzyl)-9-O-butylberberrubine chloride (Compound No.
40),
13-(4-tert-butylbenzyl)-9-O-hexylberbeπubine chloride (Compound No.
41),
13-(4-tert-butylbenzyl)-9-O-octylberberrubine chloride (Compound No.
42),
13-(4-tert-butylbenzyl)-9-O-(3-hydτoxypropyl)berberrubine chloride (Compound
No.
43),
13-(4-tert-butylbenzyl)-9-O-(6-chlorohexyl)berberrubine chloride (Compound
No.
44),
13-(4-tert-butylbenzyl)-9-O-allylberberrubine chloride (Compound No.
45),
13-(4-tert-butylbenzyl)-9-O-crotylberberrubine chloride (Compound No.
46),
13-(4-tert-butylbenzyl)-9-O-(4-tert-butylbenzyl)berberτubine chloride
(Compound No. 47),
13-(4-tert-butylbenzyl)-9-O-(4-isopropylbenzyl)berberrubine chloride
(Compound No. 48),
13-(4-isopropylbenzyl)-9-O-propylberberrubine chloride (Compound No.
49),
13-(4-isopropylbenzyl)-9-O-butylberbeπubine chloride (Compound No.
50),
13-(4-isopropylbenzyl)-9-O-hexylberberrubine chloride (Compound No.
51),
13-(4-isopropylbenzyl)-9-O-octylberbeπubine chloride (Compound No.
52),
13-(4-isopropylbenzyl)-9-O-(3-hydroxypropyl)berberrubine chloride (Compound
No.
53),
13-(4-isopropylbenzyl)-9-O-(6-chlorohexyl)berberrubine chloride (Compound
No.
54),
13-(4-isopropylbenzyl)-9-O-allylberberrubine chloride (Compound No.
55),
13-(4-isopropylbenzyl)-9-O-crotylberberrubine chloride (Compound No.
56),
13-(4-isopropylbenzyl)-9-O-(4-tert-butylbenzyl)berbeπubine chloride
(Compound No. 57),
13-(4-isopropylbenzyl)-9-O-(4-isopropylbenzyl)berbeπubine chloride
(Compound No. 58),
13-(3,4,5-trifluorobenzyl)-9-O-butylberberrubine chloride (Compound No.
59),
13-(3,4,5-trifluorobenzyl)-9-O-hexylberberτubine chloride (Compound No.
60),
13-(3,4,5-trifluorobenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 61),
13-(3,4,5-trimethoxybenzyl)-9-O-butylberberrubine chloride (Compound No.
62),
13-(3,4,5-trimethoxybenzyl)-9-O-hexylberberrubine chloride (Compound No.
63),
13-(3,4,5-trimethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 64),
13-(4-trifluoromethoxybenzyl)-9-O-butylberberrubine chloride (Compound No.
65),
13-(4-trifluoromethoxybenzyl)-9-O-hexylberberrubine chloride (Compound No.
66),
13-(4-trifluoromethoxybenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 67),
13-(4-trifluoromethylbenzyl)-9-O-butylberberrubine chloride (Compound No.
68),
13-(4-trifluoromethylbenzyl)-9-O-hexylberberrubine chloride (Compound No.
69),
13-(4-trifluoromethylbenzyl)-9-O-(4-tert-butylbenzyl)berberrubine chloride
(Compound No. 70) and pharmaceutically acceptable salts thereof. [5] A pharmaceutical composition comprising the compound as set forth in any of the aforementioned Claims 1 to 4 as an active ingredient. [6] The pharmaceutical composition as set forth in Claim 5, which is prepared in the form selected from a tablet, a capsule, a syrup, an injection, a suppository, an ointment, a cream, a lotion and a liquid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/911,371 US7915276B2 (en) | 2006-02-14 | 2006-11-06 | Berberrubine derivatives having antifungal activities |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0014146 | 2006-02-14 | ||
KR1020060014146A KR100706309B1 (en) | 2006-02-14 | 2006-02-14 | Berberrubine derivatives having antifungal activities |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007094548A2 true WO2007094548A2 (en) | 2007-08-23 |
WO2007094548A3 WO2007094548A3 (en) | 2010-10-21 |
Family
ID=38161535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/004607 WO2007094548A2 (en) | 2006-02-14 | 2006-11-06 | Berberrubine derivatives having antifungal activities |
Country Status (3)
Country | Link |
---|---|
US (1) | US7915276B2 (en) |
KR (1) | KR100706309B1 (en) |
WO (1) | WO2007094548A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102349520A (en) * | 2011-08-25 | 2012-02-15 | 华南农业大学 | Application of berberine as herbicide |
CN102464617A (en) * | 2010-11-16 | 2012-05-23 | 中国科学院兰州化学物理研究所 | Dicranostigma leptopodum berberrubine with anticancer activity and preparation method thereof |
JP2012533590A (en) * | 2009-07-20 | 2012-12-27 | ナクソスファルマ・ソシエタ・ア・レスポンサビリタ・リミタータ | Benzoquinolizinium salt derivatives as anticancer agents |
CN102894002A (en) * | 2012-11-05 | 2013-01-30 | 山东省烟台市农业科学研究院 | Compound bactericide containing berberine and polyoxins and application thereof |
CN105315208A (en) * | 2014-07-17 | 2016-02-10 | 中国科学院兰州化学物理研究所 | Aporphine type alkaloid and preparation method thereof |
CN105566317A (en) * | 2016-01-13 | 2016-05-11 | 北京宜生堂医药科技研究有限公司 | Compound and preparation method thereof |
JP2017518987A (en) * | 2014-06-11 | 2017-07-13 | マリンクロッド エルエルシー | Oxidative dearomatization of belbin. |
CN114163433A (en) * | 2021-12-21 | 2022-03-11 | 哈尔滨医科大学 | Berberine derivative and preparation method and application thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115110340B (en) * | 2022-04-24 | 2023-04-28 | 郑州大学 | Multifunctional protective liquid for paper |
CN114711243B (en) * | 2022-04-25 | 2023-09-05 | 兰州大学 | Application of berberine derivative in resisting plant pathogenic bacteria |
CN115317393A (en) * | 2022-08-30 | 2022-11-11 | 南京纽邦生物科技有限公司 | Methods and compositions for improving hair follicle, scalp or hair health in mammals |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037468A1 (en) * | 1998-12-21 | 2000-06-29 | Hanwha Chemical Corporation | DIBENZO[a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF |
WO2003051875A1 (en) * | 2000-06-22 | 2003-06-26 | Newtree Industry Co., Ltd. | New derivatives of berberrubine and their salts for antibiotics and antifungal agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100258849B1 (en) * | 1998-04-24 | 2000-08-01 | 박원배 | Pharmaceutically useful protoberberine derivative and its salts |
KR20010112798A (en) * | 2000-06-15 | 2001-12-22 | 송기원 | Protoberberine derivatives which inhibit activity of the mitogen-activated-protein kinases |
-
2006
- 2006-02-14 KR KR1020060014146A patent/KR100706309B1/en not_active IP Right Cessation
- 2006-11-06 WO PCT/KR2006/004607 patent/WO2007094548A2/en active Application Filing
- 2006-11-06 US US11/911,371 patent/US7915276B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000037468A1 (en) * | 1998-12-21 | 2000-06-29 | Hanwha Chemical Corporation | DIBENZO[a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF |
WO2003051875A1 (en) * | 2000-06-22 | 2003-06-26 | Newtree Industry Co., Ltd. | New derivatives of berberrubine and their salts for antibiotics and antifungal agents |
Non-Patent Citations (2)
Title |
---|
DATABASE CA 'Smiles rearrangement in isoquinolinium salts.' Database accession no. 108:112180 & PHARMACEUTICAL BULLETIN vol. 35, no. 6, 1987, pages 2238 - 2242 * |
PARK K D ET AL.: 'Synthesis of 13-(substituted benzyl) berberine and berberrubine derivatives as antifungal agents.' BIOORG MED CHEM LETT. vol. 16, no. 15, 01 August 2006, pages 3913 - 3916 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012533590A (en) * | 2009-07-20 | 2012-12-27 | ナクソスファルマ・ソシエタ・ア・レスポンサビリタ・リミタータ | Benzoquinolizinium salt derivatives as anticancer agents |
CN102464617A (en) * | 2010-11-16 | 2012-05-23 | 中国科学院兰州化学物理研究所 | Dicranostigma leptopodum berberrubine with anticancer activity and preparation method thereof |
CN102349520A (en) * | 2011-08-25 | 2012-02-15 | 华南农业大学 | Application of berberine as herbicide |
CN102894002A (en) * | 2012-11-05 | 2013-01-30 | 山东省烟台市农业科学研究院 | Compound bactericide containing berberine and polyoxins and application thereof |
CN102894002B (en) * | 2012-11-05 | 2013-11-20 | 山东省烟台市农业科学研究院 | Compound bactericide containing berberine and polyoxins and application thereof |
JP2017518987A (en) * | 2014-06-11 | 2017-07-13 | マリンクロッド エルエルシー | Oxidative dearomatization of belbin. |
EP3154968A4 (en) * | 2014-06-11 | 2018-02-07 | Mallinckrodt LLC | Oxidative dearomatization of berbines |
AU2015274545B2 (en) * | 2014-06-11 | 2019-02-28 | SpecGx LLC | Oxidative dearomatization of berbines |
CN105315208A (en) * | 2014-07-17 | 2016-02-10 | 中国科学院兰州化学物理研究所 | Aporphine type alkaloid and preparation method thereof |
CN105566317A (en) * | 2016-01-13 | 2016-05-11 | 北京宜生堂医药科技研究有限公司 | Compound and preparation method thereof |
CN114163433A (en) * | 2021-12-21 | 2022-03-11 | 哈尔滨医科大学 | Berberine derivative and preparation method and application thereof |
CN114163433B (en) * | 2021-12-21 | 2022-11-25 | 哈尔滨医科大学 | Berberine derivative and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US20100292476A1 (en) | 2010-11-18 |
WO2007094548A3 (en) | 2010-10-21 |
KR100706309B1 (en) | 2007-04-12 |
US7915276B2 (en) | 2011-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7915276B2 (en) | Berberrubine derivatives having antifungal activities | |
CN103059016B (en) | Coptisine derivatives, its synthetic method and anti-tumor drug purposes thereof | |
EP3299395A1 (en) | Oxidized -1,4-oligoglucuronic acid, and preparation method therefor and uses thereof | |
CN101830914B (en) | Cefuroxime lysine crystal compound and preparation method thereof | |
CN102093357B (en) | Novel indoletriazole alkaloid as well as preparation method and antifungal application thereof | |
CN102766198A (en) | Glycopeptide antifungal compound, and preparation method and application thereof | |
JP6130224B2 (en) | Novel compound lenteztrehalose, method for producing the same, use thereof, and novel microorganism | |
KR100336964B1 (en) | Antifungal agent containing obovatol or redobovatol | |
US9266852B2 (en) | Daidzein derivative, pharmaceutically acceptable salt and preparation method thereof, and pharmaceutical composition containing same | |
WO2014049356A1 (en) | Erythromycin ketolide derivatives bearing c-10 modifications | |
EP4265607A1 (en) | Aminopyridine compound and application thereof | |
CN110396090B (en) | Imidazole alcohol tetrahydrocoptisane oxime conjugate and preparation method and application thereof | |
CN106117244A (en) | The process for purification of Cefditoren pivoxil Cephalosporins | |
CN102503999B (en) | Demalonyl azalomycin F derivatives, preparation method thereof and use in preparing microbicides | |
EP3967697A1 (en) | Pyridone derivative crystal form and preparation method and application therefor | |
CN101348514B (en) | Use of starfish saponin compound extracted from Culcita novaeguineae | |
EP2468718A1 (en) | Cabanillasin, a new antifungal compound, produced by entomopathogenic xenorhabdus cabanillasii | |
TW200946678A (en) | Aminosuger compound and production method thereof | |
CN114262354B (en) | Compound and application thereof | |
JP4745560B2 (en) | Antiulcer agent | |
CN102796087A (en) | Coumarin triadimenol, and preparation method and application thereof | |
CN103265525B (en) | Substituted thiophene benzoquinone compound and preparation method and application | |
CN110437192B (en) | Compound extracted from Spongia sponge, composition, preparation method and application thereof | |
CN109384710B (en) | Three piericins natural products and application thereof in preparing anti-renal cancer drugs | |
CN104513295B (en) | Bleomycin derivative and purposes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 11911371 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06812444 Country of ref document: EP Kind code of ref document: A2 |